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Oleanolic acid but not ursolic acid induces cell death in HepG2 cells under starvation-induced 
autophagy 
 
Abstract 
 
Cancer incidence is increasing worldwide mainly due to changes in diet, life style and increased 
lifespan. In particular, liver cancer is the fifth most common cancer in the world and the third most 
common cause of cancer mortality. Plant phytochemicals are a good and promising source of anticancer 
compounds. In a previous study, we reported the potential of ursolic acid (UA) to induce cell death and to 
inhibit proliferation in colorectal cancer cells. This natural triterpenoid, UA, was also shown to activate JNK 
and to modulate molecular markers of autophagy. In the present study, the ability of two isomer 
triterpenoids, UA and oleanolic acid (OA), to induce cell death and modulate autophagy in the human 
hepatocellular carcinoma cell line (HepG2 cells) was tested. For that, the effect of these phytochemicals 
on cell death was evaluated by MTT assay and propidium iodide staining, in complete and starvation 
medium. Autophagy markers were evaluated by western blot and fluorescence microscopy. Contrary to 
our previous data with other cell lines, HepG2 cells were less susceptible to UA and, unexpectedly, OA 
was a more potent inducer of cell death than UA. Interestingly, starvation-induced autophagy sensitized 
HepG2 cells to cell death caused by OA, but not by UA. The IC50 of OA decreased from about 50 µM in 
complete medium to 3.5 µM in starvation medium. Although UA and OA increased the levels of 
autophagy markers LC3 and p62, as well as the number of acidic vacuoles (as assessed by MDC 
staining), the cell death induced by OA was not prevented by inhibitors of autophagy and of lysosome 
proteases. Overall, the results seem to indicate that autophagy is not directly involved in cell death 
induced by OA. Interestingly, methyl-β-cyclodextrin (a polymer able to decrease membrane cholesterol 
content) prevented OA-induced cell death, which indicates that disruption of cholesterol homeostasis, and 
in particular in lipid rafts, may be involved in OA effects under starvation conditions. The present results 
suggest the application of OA as a specific drug for cancer treatment in particular cell physiological 
conditions, such as under metabolic stress. 
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Potencial efeito anticancerígeno do ácido oleanólico e do ácido ursólico em células HepG2 sob 
indução de autofagia por privação de nutrientes 
 
Resumo 
 
A incidência do cancro está a aumentar em todo o mundo principalmente devido a alterações da 
alimentação, do estilo de vida e do aumento da esperança média de vida. Em particular, o cancro do 
fígado é o quinto cancro mais comum no mundo e a terceira maior causa de morte por cancro. Os 
fitoquímicos são uma excelente e promissora fonte de compostos anticancerígenos. Num estudo anterior 
o nosso grupo descreveu o potencial do ácido ursólico (AU) na indução de morte e na inibição da 
proliferação de células do cancro coloretal. Este triterpenóide de origem natural foi também descrito 
como ativador da sinalização JNK e modulador de marcadores moleculares de autofagia. No presente 
trabalho foi testada a capacidade de dois isómeros triterpenóides, o AU e o ácido oleanólico (AO), em 
induzir morte celular e modular a autofagia numa linha celular do carcinoma hepatocelular humano 
(células HepG2). Para tal, o efeito destes fitoquímicos na morte celular foi avaliado pelo ensaio de MTT e 
pela marcação com o iodeto de propídio, tanto em meio completo como em meio com privação de 
nutrientes. Os marcadores de autofagia foram avaliados por western blot e também por microscopia de 
fluorescência. Contrariamente a resultados anteriores com outras linhas celulares, as células HepG2 
foram menos suscetíveis ao AU, bem como o AO mostrou ser mais potente na indução de morte celular 
do que o AU. Além disso, a autofagia induzida pela privação de nutrientes suscetibilizou marcadamente 
as células HepG2 para a morte celular causada pelo AO, e tal já não se verificou com o AU. Nestas 
condições o IC50 do AO foi de 3,5 µM, enquanto em meio completo era de cerca de 50 µM. Embora, o 
AU e o AO aumentem os níveis dos marcadores autofágicos LC3 e p62, bem como o número de vacúolos 
acídicos (avaliado pela marcação com MDC), a morte celular induzida pelo AO não foi prevenida por 
inibidores de autofagia e nem por inibidores de proteases lisossomais. Em geral, os resultados parecerem 
indicar que a autofagia não está diretamente envolvida na morte celular induzida pelo AO. No entanto, um 
polímero capaz de diminuir o conteúdo de colesterol nas membranas celulares, a metil-β-ciclodextrina, 
preveniu a morte celular induzida pelo AO. Este resultado indica-nos que o AO pode induzir uma alteração 
na homeostasia do colesterol, em particular em domínios lipídicos ricos em colesterol, com efeitos 
drásticos sob a viabilidade das células quando estas estão sob privação de nutrientes. Estes resultados 
sugerem-nos que o AO pode ser utilizado no tratamento do cancro em condições fisiológicas específicas, 
tal como sob stress metabólico. 
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1. Cancer 
 
 
Cancer is currently a major health issue due to its high incidence being responsible for 
13% of all deaths worldwide annually. Overall, cancer is characterized by alterations in cell 
proliferation, differentiation and development due to accumulation of genetic mutations [Knowles 
and Selby, 2005]. Carcinogenesis is the process by which these changes occur and can be 
divided into three distinct phases: initiation, promotion and progression [Hennings et al., 1993]. 
During the initiation phase, irreversible mutations occur in DNA that confer cells the ability to 
grow faster and to avoid normal cellular growth control mechanisms. During the promotion 
phase, there is an increase in the proliferation ability of initiated cells. This stage is associated 
with accumulation of further mutations and the consequent formation of a mass of abnormal 
cells. The capacity of cancer cells to invade surrounding tissues and to metastasize is acquired 
through the progression phase [Abraham, 2003; Thyparambil et al., 2010]. Genes that are 
usually expressed inappropriately or mutated, such as oncogenes and tumor suppressor genes 
contribute to the development of cancer. Oncogenes act in a dominant way at the cellular level to 
drive proliferation or to prevent normal differentiation; in fact, impaired regulation of cell cycle is a 
basis for tumor formation [Knowles and Selby, 2005; Kopnin, 2000]. For example, mutational 
activation of RAS oncogene can decrease functions of checkpoints at G1 and G2 leading to 
genetic instability and consequently tumor progression [Kopnin, 2000]. Cancer development also 
occur due to inactivation/dysfunction of tumor suppressors genes, such as TP53 (tumor protein 
p53) gene that is typically mutated in most human tumors, resulting in dysfunctions of the cell 
cycle checkpoints and simultaneously inhibition of apoptosis [Levine, 1997; Orr-Weaver and 
Weinberg, 1998]. In addition to inactivating mutations in genes that provide negative regulation 
signals, such as TP53, mutation in genes of DNA repair systems can also lead to the 
development of certain tumors, since they are important to avoid mutations in other genes 
[Knowles and Selby, 2005]. 
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1.1. Liver cancer 
 
Cancer of the liver is the sixth most common cancer in the world and can have different 
etiologies. Risk factors that are associated directly or indirectly with different diseases of the liver, 
include infection with hepatitis B and C virus (HBV and HCV, respectively), contamination of food 
with aflatoxins, heavy alcohol consumption, tobacco smoking, obesity, diabetes, iron overload, 
infestation with the liver flukes, exposure to vinyl chloride, as also children affected with  
Beckwith-Wiedemann syndrome [Boffetta and Hashibe, 2006; Chuang et al., 2009; El-Serag and 
Rudolph, 2007]. Less common types of hepatic cancer include: (i) hepatoblastoma that 
represents 1% of malignances of children younger than 20 years old; (ii) cholangiocarcinoma that 
is relative to the cancer of the intrahepatic biliary ducts; and, (iii) angiosarcoma - a liver 
mesenchymal tumor that usually occurs in elderly men [Chuang et al., 2009]. The most common 
form of liver cancer is the hepatocellular carcinoma (HCC), which has a high incidence worldwide 
and cause a high number of deaths. 
 
 
1.1.1. Hepatocellular carcinoma 
 
Hepatocellular carcinoma is the most common cause of cancer mortality. The incidence 
of HCC varies widely, with high rates in sub-Saharan Africa, eastern and southeastern Asia, and 
Melanesia, and with a low incidence in Northern and Western Europe and the Americas [Parkin 
et al., 2005]. Approximately 90-95% of HCC are caused by persistent HBV and HCV infections 
(chronic hepatitis) and cirrhosis, particularly with dysplastic hepatocytes [Grisham, 2001; Motola-
Kuba et al., 2006; Seki et al., 2000; Takayama et al., 1990]. These tissue lesions are 
precancerous histological changes that normally precede HCC and allow identifying the temporal 
order with which genomic alterations develop during hepatocarcinogenesis (Figure 1) 
[Thorgeirsson and Grisham, 2002]. In western countries the HCC is caused mainly due to 
alcoholic cirrhosis [Chiesa et al., 2000].  
The hepatocarcinogenesis is the result of a multistep process characterized by the 
accumulation of genetic alterations in hepatocytes, the major cell type in the liver [Motola-Kuba et 
al., 2006]. When compared with other cancers, such as colon and breast cancers, HCC has not 
  
so predominant genetic mutations
important role in hepatocarcinogenesis, 
[Ozturk, 1999]. This gene 
overexpression of oncogenes and underexpression 
Ng, 2008]. Genetic alteration
protein from degradation and
upregulation of target genes, including the proto
1999; Thyparambil et al., 2010
HCC include mutations in 
in liver cancer 1), PTEN (phosphatase and tensin homolog)
SMAD2 (SMAD family member 2)
2) and SOCS-1 (suppressor of cytokine signaling 1) 
al., 2006]. 
 
 
 
 
1.1.2. Signaling pathways associated with hepatocellular carcinoma
 
Many signaling pathways are 
process, being the most common 
result in increased proliferation, invasion, metastasis 
Figure 1. Representation of chronological sequence of cellular lesions promoted by hepatitis B virus (HBV), hepatitis C virus 
(HCV) and  aflatoxin B1 (AFB1),  culminating in the development of hepatocellular carcinoma in human
Grisham, 2002]). 
 [Wong and Ng, 2008]. Mutations in 
and are associated with about 
mutation leads to a reduction of apoptosis and 
of other tumor suppressor genes 
s in β-catenin gene, which is involved in Wnt signaling, protect
, therefore, increase its nuclear accumulation.
-oncogene c-myc and cyclin D1
]. Other genetic alterations associated with the development of 
TP73 (tumor protein p73), Rb (retinoblastoma protein)
, IGF-2 (insulin
 and SMAD4 (SMAD family member 4), BRAC2 (breast cancer 
genes [Fujimori et al., 1991
deregulated in HCC and associated with 
activated through receptor tyrosine kinases, RTK
and survival of tumor cells
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TP53 gene, have an 
30% of HCC cases 
coincides with 
[Wong and 
s the 
 This leads to the 
 [Shtutman et al., 
, DLC-1 (deleted 
-like growth factor 2), 
; Motola-Kuba et 
 
the carcinogenesis 
s, which will 
 (Figure 2) 
s (from [Thorgeirsson and 
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[Huynh, 2010]. These include the rat sarcoma/rat sarcoma-activated factor/mitogen-activated 
protein extracellular kinase/extracellular regulated kinase (RAS/RAF/MEK/ERK) pathway, the 
phosphatidylinositide 3-kinase/protein kinase B/mammalian target of rapamycin 
(PI3K/AKT/mTOR) pathway, as well as the janus kinase/signal transducers and activators of 
transcription (Jak/Stat) and the Wnt/β-catenin signaling pathways (Figure 2) [Avila et al., 2006; 
Huynh, 2010]. In this thesis, only the PI3K/AKT/mTOR pathway was object of study. 
 
 
Figure 2. Schematic representation of pathways involved in development of HCC that modulate apoptosis, cell division, cell 
survival, and angiogenesis. Included are the rat sarcoma/rat sarcoma-activated factor/mitogen activated protein 
kinase/extracellular regulated kinase (Ras/Raf/MAP/ERK) pathway, the phosphatidylinositide 3-kinase/protein kinase 
B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway and Wnt/β-catenin pathway (modified from [Carr and Kralian, 
2010]). 
 
 
2. The PI3K/AKT/mTOR pathway 
 
 
The PI3K/AKT/mTOR is one of major signaling pathways associated with and 
constitutively activated in many types of cancer including HCC [Llovet and Bruix, 2008]. PI3K is 
activated by RTKs, such as insulin-like growth factor-1 receptor (IGF-IR) and epidermal growth 
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factor receptor (EGFR), the oncogene RAS, integrins that are molecules of cell adhesion, and G-
protein-coupled receptors (GPCRS); and is negatively regulated by the PTEN tumor suppressor 
gene [LoPiccolo et al., 2008; Wang et al., 2011b]. In tumor cells, the mechanisms for this 
pathway activation include mutations in the p110 catalytic domain of phosphoinositide-3 kinase 
(PIK3CA) gene, amplification or mutation of AKT, and loss of function of PTEN by 
underexpression or epigenetic silencing [Hu et al., 2003; LoPiccolo et al., 2008; Wang et al., 
2007; Wang et al., 2011b]. The serine/threonine kinase AKT occurs in three isoforms, AKT1, 
AKT2, AKT3, being expressed distinctively depending of the tissues, and in particular to HCC cell 
mass there is the expression of AKT2 but not of AKT1 [Xu et al., 2004; Zinda et al., 2001]. 
mTOR is a major mediator of this signaling pathway and is a downstream substrate of AKT, 
which can phosphorylate directly mTOR or indirectly by phosphorilation and inactivation of 
tuberous sclerosis complex 2 (TSC2) [LoPiccolo et al., 2008; Wang et al., 2011b]. mTOR is 
presented in two forms, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2): the first 
is implicated on control protein translation and autophagy, and promotes the expression of c-
myc, cyclin D and other genes involved in cell proliferation, growth and angiogenesis; in turn 
mTORC2 is responsible for the activation of AKT by phosphorylation at serine 473, promoting cell 
survival (Figure 4) [Carr and Kralian, 2010; Sahin et al., 2004; Sarbassov et al., 2005b]. The 
involvement of PI3K/AKT/mTOR pathway in the autophagy process is of special interest in this 
work and, therefore, it will be detailed as follow. 
 
 
3. Autophagy 
 
 
Autophagy is a cellular dynamic process of “self-eating” that was first described by de 
Duve and Wattiaux [De Duve and Wattiaux, 1966]. There are three primary forms of autophagy: 
macroautophagy, microautophagy and chaperone-mediated autophagy (CMA), differing from 
each other on their physiological functions [Rautou et al., 2010]. Macroautophagy is the most 
prevalent and commonly referred to as autophagy (term hereafter used to refer to 
macroautophagy), and is characterized as a non-selective vacuolar degradative cellular process 
by which intracellular membrane structures sequester proteins and organelles to degrade and 
turn over these materials [Meijer and Codogno, 2004]. When cells are exposed to different 
Introduction 
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situations of stress, such as nutrient starvation, oxidative stress, and hormonal signaling, 
autophagy takes place and can result in adaptation and survival, or cell death [Kondo et al., 
2005; Meijer and Codogno, 2004]. Extracellular pathogens are also eliminated in this pathway as 
part of a cellular defense mechanism [Eskelinen and Saftig, 2009; Todde et al., 2009]. The 
capacity for degradation is an important autophagic function but if unregulated it can be lethal. 
Basal levels of autophagy are important for maintaining normal cellular homeostasis and to 
generate energy and building blocks for reuse in order to cells survive under nutrient starvation 
[Kroemer et al., 2010]. However, excessive autophagy may lead to autophagic cellular death, the 
also called type II programmed cell death [Galluzzi et al., 2009]. 
In cancer cells, autophagy is suppressed during the early stages of tumorigenesis, 
because there is a need of higher level of protein synthesis than protein degradation to promote 
tumor growth [Cuervo, 2004]. In addition, with inhibition of autophagy there is less removal of 
damaged organelles, which allows accumulation of genotoxic free radicals contributing for cancer 
promoting stages [Edinger and Thompson, 2003]. Although autophagy is generally decreased in 
cancer cells compared with normal ones, in later stages of tumorigenesis stimulation of 
autophagy is observed in cancer cells that are located in the central areas of the tumor, where 
there is poor vascularization allowing them to survive under conditions of nutrient starvation and 
low oxygen conditions [Cuervo, 2004]. In addition, induction of autophagy was also observed in 
response to anticancer drugs, and therefore, autophagy is currently viewed as a good target for 
cancer therapy [Bursch et al., 2000; Inbal et al., 2002; Paglin et al., 2001]. 
 
 
3.1. The process of autophagy 
 
Autophagy is an evolutionarily conserved lysosomal degradation pathway that occurs in 
all eukaryotic cells, from yeast to mammals [Klionsky and Emr, 2000; Meijer and Codogno, 
2004]. The autophagic process begins with the sequestration of cytoplasmatic constituents, 
including organelles, by a double-membrane-bound structure known as phagophore or isolation 
membrane [Mizushima, 2007; Stromhaug et al., 1998]. The elongation and complete closure of 
the phagophore, results in the formation of the autophagosome, which after maturation fuse with 
lysosome to form the autolysosome. Then, the sequestered content together with the inner 
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autophagosomal membrane are degraded by acidic lysosomal hydrolases for recycling (Figure 3) 
[Mizushima, 2007; Shintani and Klionsky, 2004]. 
Several Atg (autophagy-related) proteins are necessary to the execution of autophagy and 
have been first characterized in yeast, and many of these have mammalian orthologs [Yang et 
al., 2005]. Together with other autophagy proteins, the class III PI3K, also named human 
vacuolar protein sorting (hVps34) is involved in initial formation of the phagophore membrane, as 
well as in the sequestration of all contents that will be degraded [Liang et al., 1999; Petiot et al., 
2000; Sun et al., 2008]. The first evidence of implication of this enzyme in the autophagic 
process was due to discovery of 3-methyladenine (3-MA) that is able to block the formation of 
autophagosomes by inhibition of class III PI3K (Figure 3) [Blommaart et al., 1997b; Furuya et al., 
2005; Petiot et al., 2000; Zeng et al., 2006]. BECLIN 1 was the first tumor suppressor gene 
related with autophagy to be reported, and its interaction with class III PI3K is necessary for 
autophagy. BECLIN 1, can be inhibited by the interaction with the antiapoptotic protein BCL-2 
[Sinha and Levine, 2008; Yang et al., 2005]. In other words, dissociation of BECLIN 1 from BCL-
2 is necessary to occur induction of autophagy and, consequently, there is a relationship between 
the induction of autophagy and increased expression of BECLIN 1 [Liang et al., 1999; Nice et al., 
2002]. Microtubule-associated protein light chain 3 (LC3), a mammalian homolog of yeast Atg8, 
is a major constituent of the autophagosomes and also important for their formation [Mizushima 
et al., 2004]. LC3 is synthesized as a pro-protein that is cleaved at the glycine residue, forming 
the cytosolic LC3-I [Farkas et al., 2009]. The C-terminal glycine of LC3-I when coupled to 
phosphatidylethanolamine through an ubiquitin-like conjugation reaction result in the formation of 
LC3-II [Ichimura et al., 2000; Kabeya et al., 2004]. LC3-II is important for the elongation and 
closure of the phagophore and remains associated with the inner and outer membrane of the 
autophagosome (Figure 3) [Nakatogawa et al., 2007]. After fusion with the lysosome, the LC3-II 
content in the autolysosome decreases either by cleavage (outer) or by degradation by lysosomal 
enzymes (inner membrane-associated) [Kabeya et al., 2000; Mizushima et al., 2010]. 
Consequently, LC3-II is considered as a good autophagy marker [Kouri et al., 2002]. p62 
protein/sequestome 1 (p62/SQSTM1) is a ubiquitin-binding protein that binds directly to LC3-II 
and is transported into the autophagosome, where it will be degraded on the final phase of the 
autophagic process [Ichimura and Komatsu, 2010]. p62 is also used as marker of autophagic 
flux, because when occurs a inhibition or induction of autophagy, there is an accumulation or 
decline of p62 levels, respectively [Bjorkoy et al., 2009]. 
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Figure 3. Schematic illustration of the autophagic process. Autophagy begins with the isolation of a double membrane that 
sequesters and engulfs cellular proteins, organelles and cytoplasm to form a double membrane vesicle named autophagosome. 
The isolation membranes elongate and mature, with the necessary recruitment of the microtubule-associated protein 1 light chain 
3 (LC3). The formation of the pre-autophagosomal structure can be inhibited by the class III PI3K inhibitor 3-methyladenine (3-
MA). Lysosomes fuse with autophagosomes and intraautophagosomal contents are lysed by lysosomal hydrolases for recycling. 
This process can be inhibited by lysosomotropic agents such as chloroquine [Andjelkovic et al., 1997]. Pepstatin A (PepA) and 
E64d, inhibitors of cathepsins, also inhibit the final step of autophagy that is the degradation of intraautophagosomal contents. 
Represented are also other forms of inhibition of autophagy, either pharmacologically or by molecular tools (modified from [Mehta 
and Siddik, 2009]). 
 
 
3.2. Regulation of autophagy 
 
Autophagy has an important role in cancer and the initial signals that induce autophagy 
are mainly due to stress conditions, such as anticancer treatments, and low nutrient availability 
[Kondo et al., 2005]. There is thus a growing interest in pathways and molecules that regulate 
autophagy that can be used as targets in cancer treatment [Sridharan et al., 2011]. The 
autophagic process and the molecular machinery associated suggest that its regulation can be 
complex and may involve multiple signaling inputs [Periyasamy-Thandavan et al., 2009]. Kinases 
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such as mTOR, PI3K and AKT play an essential role in induction or inhibition of autophagy 
depending on different stimuli, where mTOR occupies an important position because it is the 
principal regulator of autophagy [Periyasamy-Thandavan et al., 2009]. Bellow will be described 
the most important pathways that regulate autophagy. 
 
3.2.1. Amino acid signaling 
 
The amino acids are the major end products of protein degradation process in autophagy 
and promote its regulation by inhibition of this process, maintaining cellular homeostasis [Yang et 
al., 2005]. However, not all amino acids are involved in autophagy regulation [Mortimore and 
Poso, 1987; Periyasamy-Thandavan et al., 2009; Seglen et al., 1980]. In particular, alanine, 
leucine, glutamine and phenylalanine seem to be effective inhibiting autophagy [Bergamini et al., 
1995; Mortimore et al., 1991; Seglen et al., 1980]. These amino acids have their own 
recognition sites at the cell surface and promote signal transduction that will act by 
phosphorylation of mTORC1 through the Ras-related small GTPases (Rag proteins), suppressing 
autophagy [Kadowaki et al., 2006; Kim et al., 2008a; Long et al., 2005]. The stimulation of 
autophagy through nutrient starvation (nitrogen starvation) was first demonstrated by Schworer 
and Mortimore in 1977 [Chan et al., 2006a]. Recently, it was demonstrated that it is L-glutamine 
that is the rate-limiting factor that enables amino acids shortage to inhibit mTORC1 signaling 
[Mortimore and Schworer, 1977; Nicklin et al., 2009]. Under conditions of availability of 
extracellular amino acids the influx of L-glutamine by its high-affinity transporter SLC1A5 (solute 
carrier family 1 member 5) occurs increasing its intracellular concentration (Figure 4) [Ravikumar 
et al., 2010]. The heterodimeric SLC7A5 (solute carrier family 7 member 5)/SLC3A2 is a 
bidirectional antiporter that uses L-glutamine as an efflux substrate in exchange for the cellular 
uptake of essential amino acids that consequently allows activation of mTORC1 through the Rag 
GTPases [Nicklin et al., 2009]. The stimulation of autophagy by amino acid starvation reproduces 
what happens in advanced stages of cancer, where autophagy may be required to provide 
essential nutrients to cells in the inner part of a solid tumor that do not have direct access to the 
blood supply [Ogier-Denis and Codogno, 2003]. 
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3.2.2. Insulin/Insulin-like Growth Factor signaling 
 
The pathways through which hormones regulate autophagy are distinct from those 
regulated by nutrients, but both converge in the activation or inhibition of the key regulator of 
autophagy - mTOR. The hormone insulin that is secreted by the pancreas in response to high 
blood glucose, binds to its receptor (insulin receptor – IR) on the surface of cells and promotes 
its autophosphorylation on tyrosine residues. This induces the recruitment and phosphorylation of 
IRS1 and IRS2 (insulin receptor substrate 1 and 2) [He and Klionsky, 2009; Neely et al., 1977; 
Pfeifer, 1978]. The insulin-like growth factor is mainly secreted in the liver as a result of 
stimulation by the growth hormone, and has the same effect on the IR as insulin. High levels of 
circulating insulin-like growth factor 1 (IGF1) and certain genetic polymorphisms of IGF1 are 
associated with increased risk of several cancers [Tao et al., 2007]. In association with the 
phosphorylation of insulin receptors, p85 (a regulatory subunit of class I PI3K) promotes 
activation of PI3K (Figure 4) [Yang et al., 2005]. Thereby, activation of PI3K generates 
phosphatidylinositol (3,-4,-5)-triphosphate (PIP3) that allows membrane recruitment of AKT and 3’ 
phosphoinositide-depedent kinase 1 (PDK1) [Alessi et al., 1997; Stokoe et al., 1997]. This last in 
turn phosphorylates and activates AKT, leading to activation of mTOR and thus inhibition of 
autophagy (Figure 4) [Blommaart et al., 1997a; Klionsky, 2004]. This effect can be reversed by 
the tumor suppressor gene PTEN, which reverse PIP3 production and decreases the downstream 
AKT signaling, positively regulating autophagy (Figure 4) [Arico et al., 2001]. 
 
3.2.2.1. PI3K 
The enzymes PI3K catalyze the phosphorylation of the 3’ position hydroxyl group of the 
inositol ring in phosphatidylinositol, and have been classified into three classes [Cantley, 2002]. 
Each class has its own structure, function, substrate specificity and lipid products [Engelman et 
al., 2006; Katso et al., 2001]. The classes I PI3K is often activated in response to growth factors 
and once activated, the generated PIP3 binds to the pleckstrin homology (PH) domains of PDK-1 
and AKT, leading to the translocation of both proteins to the cell membrane where they are 
consequently activated (Figure 4) [Adjei and Hidalgo, 2005; LoPiccolo et al., 2008]. About the 
class II PI3K little is known of their function but it is thought to play a role in processes such as 
cell migration and vascular smooth muscle contraction [Domin et al., 2005; Wang et al., 2006]. 
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The class III PI3K specifically produces the lipid phosphatidylinositol 3-phosphate (PI3P) and is 
involved in the formation of autophagosomes and initiation of autophagy [He and Klionsky, 2009; 
Schu et al., 1993; Volinia et al., 1995; Yang et al., 2005]. The sole member of class III PI3K is 
hVps34 and was first identified as an important regulator of vesicular trafficking in the 
endosomal/lysosomal system [Lindmo and Stenmark, 2006; Odorizzi et al., 2000]. It is 
implicated in the recruitment of proteins that have PI3P binding domains to the intracellular 
membranes [Backer, 2008; Lindmo and Stenmark, 2006; Odorizzi et al., 2000]. hVps34 
interacts with the autophagy-related proteins such as BECLIN 1, UVRAG (UV radiation resistance-
associated gene), Bif-1 (Bax-interacting factor 1) and p150 (Vps15 in yeast), forming a complex 
that produces PI3P by phosphorylation of phosphatidylinositol (PI) important for the execution of 
autophagy [Furuya et al., 2005; Kihara et al., 2001; Liang et al., 2006; Takahashi et al., 2007]. 
 
3.2.2.2. AKT 
AKT is a serine/threonine kinase also named protein kinase B (PKB), which is activated 
by various signals upstream class I PI3K, resulting in the phosphorylation of multiple downstream 
effectors [Nogueira et al., 2008; Vivanco and Sawyers, 2002]. This kinase is present in three 
isoforms, AKT1, AKT2 and AKT3, and their activation occur first by phosphorylation at threonine 
308 in the catalytic domain by PDK-1 and then requires a subsequent phosphorylation at serine 
473, which can be mediated by several kinases such as PDK-1, AKT itself or mTORC2 complex 
[Andjelkovic et al., 1997; Balendran et al., 1999; Santos et al., 2001; Toker and Newton, 2000]. 
Once activated, one of the downstream effectors of AKT is the tumor suppressor proteins 
mutated in tuberous sclerosis which form a complex named the tuberous sclerosis complex 
(TSC) [Ravikumar et al., 2010]. TSC consists of TSC1 and TSC2, where their phosphorylation is 
inhibitory by blocking TSC2 interaction with TSC1. This leads to activation of the GTP-binding 
protein Rheb (Ras homolog enriched in Brain), which directly binds and activates the mTORC1 
resulting in protein synthesis, cell growth and suppression of autophagy (Figure 4) [Gao et al., 
2002; Mathew et al., 2009; Ravikumar et al., 2010; Teckman and Perlmutter, 2000]. 
 
3.2.2.3. mTOR 
The serine/threonine kinase mTOR is the master regulator that integrates upstream 
pathways that include the response to insulin/growth factor signaling through PI3K/AKT and to 
nutrient and energy conditions (see 3.2.1 and 3.2.3), leading to the regulation of autophagy and 
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other cellular functions, such as initiation of mRNA translation, cell growth and proliferation, and 
transcription [Sarbassov et al., 2005a]. mTOR can exist in two distinct protein complexes, of 
which only one is involved directly with autophagy regulation. 
Rapamycin-sensitive mTORC1 consists of the mTOR catalytic subunit, RAPTOR 
(regulatory associated protein of mTOR) mLST8 (mammalian LST8) and PRAS40 (proline-rich Akt 
substrate of 40 kDa) [Guertin and Sabatini, 2009; Yang and Guan, 2007]. When activated, 
mTORC1 phosphorylates the ribosomal protein S6 kinase 1 (S6K1 also named p70S6K) to 
positively regulate the translation of mRNAs containing 5’ terminal oligopyrimidine tract (5’ Top). 
In addition, the eukaryotic initiation factor 4E binding protein-1 (4E-BP1) is also phosphorylated 
by mTORC1, which induces its dissociation from the eukaryotic initiation factor 4E (eIF4E), 
liberating this factor to bind the 5’ terminal cap structure of RNA promoting the initiation of 
translation [Yang et al., 2005]. mTORC1 also phosphorylates and regulates proteins involved in 
autophagy (Figure 4). Active mTORC1 interacts with and phosphorylates the UNC51-like kinase 
1/2 (ULK1/2) and Atg13, leading to their inhibition, and together with FAK family – interacting 
protein of 200 kDa (FIP200) form a ULK1/2-Atg13-FIP200 complex that promote inhibition of 
autophagy [Ravikumar et al., 2010]. Under starvation conditions or rapamycin treatment, 
mTORC1 is inhibited due to the dissociation of mTOR from the complex. Inactive mTORC1 
dissociates from the ULK1/2-Atg13-FIP200 complex resulting in the dephosphorylation of 
ULK1/2, activating it, which promotes the ULK1-mediated phosphorylations of Atg13, FIP200, 
and ULK1 itself, triggering the autophagy cascade (Figure 4) [Ganley et al., 2009; Hosokawa et 
al., 2009; Jung et al., 2009; Ravikumar et al., 2010]. Therefore, the ULK1/2-Atg13-FIP200 
complex signals the autophagic machinery downstream of mTORC1. 
In contrast, rapamycin-insensitive mTORC2 is composed by mTOR, RICTOR (rapamycin-
insensitive companion of mTOR), mLST8 and Sin1 (SAPK-interacting protein 1), and it is able to 
phosphorylate members of the AGC kinase family, such as AKT and protein kinase C (PKC), 
promoting cellular survival and actin cytoskeleton organization, respectively [Jacinto et al., 2004; 
Sarbassov et al., 2004]. 
 
3.2.2.4. Feedback mechanism that regulates autophagy 
The role of mTOR in regulation of autophagy can also involve the mTORC2 complex 
(Figure 4). Chen et al. have shown that low concentrations of rapamycin induce AKT 
phosphorylation by inhibition of mTORC1 but higher concentrations suppress AKT 
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phosphorylation through inhibition of mTORC2 [Chen et al., 2010]. The mTORC2 have an 
important role in activation of AKT that is implicated in the phosphorylation and inactivation of the 
forkhead box O3 (FOXO3) transcriptional factor, which has been reported to stimulate autophagy 
by increasing the expression of proteins involved in autophagy, such as LC3 and BCL-
2/adenovirus E1B 19 kDa protein – interacting protein 3 (Bnip3) [Brunet et al., 1999; 
Mammucari et al., 2007; Sarbassov et al., 2005b].  
 
 
 
Figure 4. Schematic representation of mTOR-dependent main pathways regulating autophagy. The activation of PI3K pathway 
trough binding of insulin (or growth factors) to insulin receptor (IR) leads to activation of AKT, and in turn inhibition of TSC-1/2 
complex that promotes activation of Rheb and consequently mTORC1. AKT can also be phosphorylated and activated by 
mTORC2. Downstream of mTORC1, the ULK1-Atg13-FIP200 complex acts as an integrator of the autophagy signals. Under 
nutrient-rich conditions, mTORC1 suppresses autophagy by interacting with this complex and mediating phosphorylation 
dependent inhibition of Atg13 and ULK1. Under starvation conditions or rapamycin treatment, mTOR dissociates from the 
complex, resulting in dephosphorylation-dependent activation of ULK1 and ULK1-mediated phosphorylations of Atg13, FIP200, 
and ULK1 itself, which triggers autophagy. Amino acids activate mTORC1 via Rag GTPases and suppress autophagy, being L-
glutamine the rate limiting factor. The mTORC1 pathway regulates cell growth mainly through 4E-BP1 and p70S6K. 
Phosphorylation dependent activation of p70S6K can also inhibit IRS1, thereby exerting a negative feedback loop mechanism 
(modified from [Ravikumar et al., 2010]). 
Glucose 
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Therefore, mTORC2 can negatively regulate autophagy indirectly by AKT through a negative 
feedback loop. In addition, autophagy can be also regulated by other feedback loop through 
p70S6K [Scott et al., 2004]. Once activated by PI3K/AKT signaling, mTOR/p70S6K 
phosphorylates the IRS-1 on serine residues, resulting in its inhibition by targeting it to 
degradation. This work as a negative feedback loop that attenuate PI3K/AKT signaling, and 
therefore mTOR activity (Figure 4) [Manning and Cantley, 2007; O'Reilly et al., 2006; Ravikumar 
et al., 2010]. 
 
3.2.3. Energy-dependent AMPK signaling 
 
The autophagic process is ATP-dependent and lower cellular energy levels (for example, 
due to glucose starvation or other stress) signals mTORC1 by activating AMPK [Chan et al., 
2006b; Farkas et al., 2011]. AMPK, which senses changes in the intracellular ATP/AMP ratio, 
directly phosphorylates TSC2, thereby providing the priming phosphorylation for subsequent 
phosphoryalation of TSC2 by glycogen synthase kinase 3 (GSK-3) to inhibit mTOR signaling, 
thereby inducing autophagy and inhibiting protein synthesis (Figure 4) [Hoyer-Hansen and 
Jaattela, 2007; Inoki et al., 2006]. 
 
 
4.  Autophagy and lipids 
 
 
Autophagy is an essential cellular process that mediates the degradation of intracellular 
components since they are dysfunctional or to meet cellular energetic demands. Therefore, 
during nutrient deprivation not only autophagic degradation of cytosolic proteins and organelles 
are in place, but also lipid and glycogen stores are mobilized for energy production (Figure 5) 
[Eskelinen and Saftig, 2009; Singh and Cuervo, 2011; Todde et al., 2009]. Lipids are essential to 
all organisms as substrates for energy production, as precursors of membrane lipids and as 
signaling molecules of several cellular processes. The cells store the lipids as triglycerides in the 
form of dynamic organelles called lipid droplets (LD) that, when necessary, are breakdown into 
free fatty acids by the process of lipolysis [Martin and Parton, 2006]. Both autophagy and 
lipolysis are regulated hormonally by insulin and glucagon and are increased during starvation 
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[Mizushima and Klionsky, 2007; Singh et al., 2009a]. Interestingly, it has been established 
recently a link between these two catabolic processes, in which part of lipid droplets have been 
incorporated into autophagic vesicles of double membrane, that subsequently fuse with 
lysosomes, for degradation of their contents (Figure 5) [Singh et al., 2009a]. Genetic or 
pharmacology inhibition of autophagy in hepatocytes resulted in increased content of triglycerides 
(TG) and LD, supporting the idea that lysosomal degradation of intracellular LD by autophagy is a 
constitutive process and that can also contribute to lipid mobilization in vivo [Singh et al., 2009a]. 
However, other study revealed that autophagy is involved in LD formation, during starvation in 
hepatocytes and cardiomyocytes. The lipidated LC3 protein required for autophagosome 
formation was shown to be present in isolated LD. In addition, knockout of the essential 
autophagy gene Atg7 led to a reduced content of LD during fasting [Shibata et al., 2009]. These 
contrasting effects between both studies may be due to the model used: in the first adult mice 
were used whereas in the second young mice were used [Rodriguez-Navarro and Cuervo, 2010]. 
Interestingly, studies in pre-adipocytes in culture also showed that autophagy can regulate 
adipogenesis (the differentiation process of pre-adipocytes into mature adipocytes) [Singh et al., 
2009b].  
Despite the importance of autophagy to regulate lipid metabolism, many evidences also 
support that lipids and lipid modifications modulate autophagy. For example, it has been reported 
that exposure of cells to a high lipid load significantly decreases the degradation of proteins 
mainly due to reduced autophagy [Koga et al., 2010]. This high lipid load affects the cholesterol 
content of membranes reducing it, which can lead to defects in the membrane fusion between 
autophagosome and lysosomes, inhibiting therefore autophagy in later steps [Koga et al., 2010]. 
Conversely, a previous study reports that depletion of cholesterol in fibroblasts induces 
autophagy [Cheng et al., 2006]. However, these authors studied autophagy only by measuring 
LC3 levels by western blot and immunofluorescence. They observe a significant increase of LC3 
that suggest them to be in the presence of increased of autophagic activity. However, it is known 
currently that this effect is most probably due to the inhibition of autophagy at later steps 
[Mizushima et al., 2010]. Also CMA is known to be affected by cholesterol levels. The receptor of 
this autophagic pathway, LAMP-2A, associates in a dynamic manner with lipid microdomains 
(enriched in cholesterol and sphingolipids) at the lysosomal membrane. LAMP-2A undergoes 
regulated degradation in these regions, and therefore lower cholesterol levels will increase CMA 
activity [Rodriguez-Navarro and Cuervo, 2010]. The PI3P lipid molecules are also required and 
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essential for autophagy execution, serving as a scaffold for the assembly of autophagosomes, 
their trafficking in microtubules, lysosomal fusion and possibly in cargo recognition [Singh and 
Cuervo, 2011]. Therefore, modulation of these lipid molecules by the coordination between 
kinases and phosphatases are essential for regulating autophagy. 
 
 
 
 
 
Figure 5. Macroautophagy contributes to the delivery of proteins, lipid stores, and glycogen for breakdown into lysosomes. The 
constituent components of these macromolecules exit the lysosome and become available for production of energy. In the case of 
protein breakdown, the resulting amino acids may have less energetic value and be preferentially utilized for the synthesis of new 
proteins. Levels of amino acids, free fatty acids, and sugars circulating in blood or in the extracellular media have a direct impact 
on intracellular marcoautophagy (from [Singh and Cuervo, 2011]).  
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5. Cancer therapy and pharmacological autophagy modulation 
 
 
Autophagy is a process with an important role in cancer development and therapy. 
Increased levels of autophagy are commonly observed in tumor cells after cancer therapy, such 
as by radiotherapy, with chemotherapeutics (e.g., doxorubicin, temozolomide, camptothecin), by 
histone deacetylase inhibitors and with hormonal therapeutics (e.g., tamoxifen) [Roy and 
Debnath, 2010]. Considering that increased autophagic activity provide resistance of cancer cells 
to anticancer treatment, inhibitors of autophagy have been proposed as good adjuvants for 
cancer therapy [Roy and Debnath, 2010]. In established tumors, increased autophagy has been 
reported in central parts of the tumor as a strategy for survival in a very stressful and nutrient-
deprived environmental. Autophagy-dependent cell death has also being explored in cancer 
treatment, where extensive degradation of cytoplasmic materials beyond a critical point is 
believed to drive cell death. Therefore, the signaling pathways that regulate autophagy and also 
proliferation and apoptosis, which commonly are altered in cancer, are therefore potential 
therapeutic targets (Figure 6) [Kondo et al., 2005].  
A range of chemical inhibitors of autophagy, such as 3-MA, chloroquine (CQ), pepstatin A 
(PepA) and E64d, LY-294002 and wortmannin, can be used to study the role of autophagy in 
tumorigenesis and in response to therapy (Figure 6). However, due to lack of specificity, low 
solubility and/or high toxicity of many of these compounds, their clinical application is 
compromised of low value. For example, 3-MA inhibits both class I and class III PI3K; the 
inhibition of class I PI3K is persistent, whereas its effect on class III PI3K is transient, providing a 
temporal different effect and an inhibition of autophagosome formation [Bursch et al., 1996; Wu 
et al., 2010]. In addition to 3-MA, other pharmacologic agents such as LY-294002 and 
wortmannin target the p110 catalytic subunit of class I PI3K, but also lack specificity like 3-MA, 
which compromise also their use in modulating autophagy [LoPiccolo et al., 2008]. Chloroquine, 
known as an anti-malarial drug, is an inhibitor of lysosomal acidification, because leads to 
disruption the lysosomal pH gradient. Thus, it blocks the terminal stages of autophagic 
proteolysis by preventing the fusion of autophagosomes with lysosomes. Currently, CQ is being 
tested in clinical trials for cancer treatment through autophagy inhibition [Farkas et al., 2011; Roy 
and Debnath, 2010; Yamamoto et al., 1998]. The inhibition of lysosomal function by inhibition of 
cathepsins is another form of promoting the blockage of autophagy. To do this experimentally it 
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can be used a combination of PepA and E64d, two inhibitors of cathepsins, in which PepA is a 
membrane-permeable inhibitor of cathepsins D and E, whereas E64d is a membrane-permeable 
inhibitor of cathepsins B, H and L [Kirschke and Wiederanders, 1987; Tamai et al., 1987; Tanida 
and Waguri, 2010; Umezawa et al., 1970]. Inhibition of these proteases will promote a blockage 
of the final step of autophagy, easing the evaluation of autophagic flux [Kim et al., 2008b].  
 As discussed above, inhibition of mTOR (and, therefore, induction of autophagy) is also a 
strategy to kill cancer cells since they have a higher demand on protein synthesis [Cuervo, 
2004]. Frequently, rapamycin is used to inhibit mTOR and exhibits considerable anticancer 
activity (Figure 6) [Faivre et al., 2006]. However, therapy mediated by rapamycin shows some 
problems, such as the need of a wide dose range to inhibit mTOR under different conditions, as 
also the resistance to therapy through mechanism of negative feedback loop [Chen et al., 2010; 
Foster and Toschi, 2009]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic representation of PI3K/AKT/mTOR pathway with targets of the pharmacological inhibitors with modulatory 
effects in autophagy (from [LoPiccolo et al., 2008]). 
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6. Natural compounds and cancer 
 
 
Throughout of time, natural compounds from plants, marine organisms and 
microorganisms have been a rich source of agents that are used in many applications and fields, 
including in medicine, due to their structural diversity and bioactive potential [Nobili et al., 2009]. 
Today, the natural products play a relevant role in cancer therapy and others are in development 
with a significant number of compounds in different phases of clinical trial [Cragg et al., 1997; 
Gordaliza, 2007]. In fact, a high percentage of pharmaceutical drugs in use are of natural origin 
or develop from research in natural compounds, where most of them are used in anticancer 
treatment [Cragg et al., 1997; Newman et al., 2000].  
Due to the diverse molecular alterations that occur in cancer cells that are associated 
with their tumorigenesis, the structural diversity of natural compounds make them good source of 
potential anticancer drugs with a specific target of action or multi-targets in key cancer regulators. 
In addition, natural compounds are a more attractive option than standard chemotherapy agents, 
due to their recognized low-toxicity [West et al., 2002]. Therefore, these chemicals of natural 
origin can contribute to decrease resistance of anticancer treatments or to be used as substitutes 
of common agents in chemotherapy [Roy and Debnath, 2010]. 
 
 
6.1. Triterpenoids 
 
Plants synthesize a large number of secondary metabolites, including many 
phytochemicals, such as phenolic compounds, essential oils, alkaloids and terpenes. Terpenes 
are compounds with a cyclic structure and based on the C5 isoprene units [Cowan, 1999]. 
Triterpenoids are composed from six isoprene units (C30H48), where additional elements, 
normally oxygen, are added [Cowan, 1999; Phillips et al., 2006]. Triterpenoids are aglycones, 
but when linked to one or more sugar chains are in turn named triterpenoid saponins [Price et 
al., 1987]. 
Throughout of years, triterpenoids were considered to be biologically inactive. But their 
low toxicity profile led to their use for medicinal purpose in many countries, primordially in Asia, 
and evidences of their pharmacologic activities of triterpenoids have been emerging [Bishayee et 
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al., 2011]. The anticancer efficacy of several triterpenoids has been recently reported, where 
these compounds exhibit cytotoxicity against a variety of cancer cells without major toxicity in 
normal cells [Laszczyk, 2009; Petronelli et al., 2009; Setzer and Setzer, 2003]. In the present 
work we used two pentacyclic triterpenoid isomers – ursolic acid (UA) and oleanolic acid (OA). 
 
 
6.1.1. Ursolic acid 
 
Ursolic acid (3β-hydroxy-urs-12-en-28-oic acid) is a pentacyclic triterpene compound that 
exists in plants, medicinal herbs and fruits (Figure 7). UA has shown interesting biological 
activities such as anti-inflammatory, anti-hyperlipidemic, antioxidant, anti-angiogenic and 
anticancer effects [Banno et al., 2004; De Angel et al., 2010; Ramos et al., 2010; Sohn et al., 
1995]. Thereby, this triterpenoid has been shown to inhibit the growth of tumor cells through cell 
cycle arrest and induction of apoptosis in many cancer cell types [Harmand et al., 2003; Tang et 
al., 2009]. Related to apoptosis induction, it was reported recently that UA activated caspase -3, -
8, and -9, as well as downregulated the expression of BCL-2 in gastric cancer cells [Wang et al., 
2011a]. It has also been suggested that UA may be involved in modulation of autophagy through 
activation of JNK signaling, and in turn exerting anticancer effects in apoptosis-resistant HCT15 
colorectal cancer cells [Xavier et al., 2012, submitted]. In HCC, it has been reported that UA 
induces apoptosis through activation of caspase 3 and cell cycle arrest via inhibition of DNA 
replication and increased p21 expression [Kim et al., 2000]. In other study, it  was also observed 
that UA decreased the activation of nuclear transcription factor NF-kB and its downstream 
effectors BCL-2 and X-linked inhibitor of apoptosis protein (XIAP), the later with ability to inhibit 
caspase-3, -7, and -9 [Shyu et al., 2010; Stennicke et al., 2002]. UA was also able decrease the 
mitochondrial membrane potential of the HCC cells HuH7 with the consequent release of 
cytochrome c from the mitochondria into the cytosol and with activation of caspases [Shyu et al., 
2010; Yan et al., 2010]. In breast cancer cells, UA inhibited migration and invasion of tumor cells 
through suppression of AKT/mTOR and NF-kB signaling, with the corresponding decrease of 
matrix metalloproteinase (MMP) levels [Yeh et al., 2010]. Anti-angiogenic effects of UA by 
decreasing the expression of vascular endothelial growth factor (VEGF), interleukin-8, and 
transcription factor HIF-1α was also reported in liver cancer [Lin et al., 2011], while in melanoma 
cancer cells UA suppressed VEGF, MMP-2 and MMP-9 [Kanjoormana and Kuttan, 2010]. 
Introduction 
 
23 
 
 
6.1.2. Oleanolic acid 
 
Oleanolic acid (3β-hydroxy-olea-12-en-28-oic acid) is a isomer of UA, differing these two 
compounds in the position of a methyl residue (Figure 7). In OA a methyl group is together with 
other in position 20, while in UA the methyl group is in position 19 of the cyclic ring system [Liu, 
1995]. Like UA, it has been shown that OA possess many biological activities such as anti-
inflammatory, anticancer, antiviral, hepatoprotective and anti-hyperlipidemic effects, occurring in 
more than 120 plants species [Chen et al., 2011; Wang and Jiang, 1992]. The antitumor activity 
of OA has been reported in colon cancer cells due to its inhibitory effect on cell proliferation 
through cell cycle arrest [Li et al., 2002]. The apoptotic effects of OA was described in leukemia 
cells, in which it activated caspase-9 and caspase-3, accompanied by the cleavage-induced 
inactivation of the DNA repair enzyme Poly (ADP-ribose) polymerase [Zhang et al., 2007]. It has 
also been shown that OA downregulates the expression of cyclin D1 and upregulates p21 and 
p27, that inhibits the activation of the nuclear translocation of transcription factors such as NF-
kB, c-fos, ATF-2 and CREB-1, and that also downregulates the production and expression of TNF-
α, IL-1β and IL-6, in melanoma cells [Pratheeshkumar and Kuttan, 2011]. In HCC cells, OA 
induced also apoptotic effects via increasing DNA fragmentation, decreasing mitochondrial 
membrane potential, lowering Na+-K+-ATPase activity, and elevating caspase-3 and caspase-8 
activities [Yan et al., 2010]. In other HCC cell lines, it was reported the antiproliferative effects of 
OA through apoptosis associated with alterations in BCL-2 family proteins and downregulation of 
NF-kB and XIAP [Shyu et al., 2010]. OA was also able to suppress cell adhesion and to reduce 
the production of VEGF and the intercellular adhesion molecule 1 - ICAM-1 [Yan et al., 2010]. In 
osteosarcoma cells, OA inhibited both mTORC1 downstream targets S6K, and 4E-BP1, induced 
cell cycle arrest and inhibited mTORC2 and its target AKT, leading to induction of apoptosis 
[Zhou et al., 2011]. 
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Figure 7. Struc
 
 
7. Triterpenoids and cholesterol
 
 
Cholesterol is a molecule formed by squalene cyclization and 
synthesized or absorbed from the diet 
cellular membranes and modulates various of their properties such as fluidity, permeability, 
stability and contour [Deng et al., 2009
concentration of cholesterol in its 
the phospholipids of membranes, integrating regions with a characteristic structural composition 
that appear to act as platforms to colocalize proteins, these microdomains
[Calder and Yaqoob, 2007]. Such 
include signal transduction, membrane trafficking, cytoskeletal organization and pathogen entry 
[Ikonen, 2001]. As mentioned before, 
autophagy, in particular in the fusion of autophagosome
 
 
 
 
 
 
 
ture of ursolic acid, oleanolic acid and cholesterol. 
 
in humans can be 
[Stryer et al., 2002]. It is an essential component of 
]. Lysosome is one of the organelles that contain a high 
membrane [Gallegos et al., 2002]. Cholesterol can interact with 
 are named 
lipid rafts play important roles in several cellular process that 
cellular cholesterol levels can have dramatic effects in 
s with lysosomes [Koga et al.
Cholesterol 
lipid rafts 
, 2010]. The 
Introduction 
 
25 
 
proteins involved in fusion of the two compartments, such as SNAREs- mediated vesicular fusion, 
are localized in these microdomains and their activity are affected by depletion of cholesterol 
[Koga et al., 2010]. Another effect of low cholesterol in lysosomal membrane is the increased 
permeability to K+ and H+, destabilizing the lysosomes by affecting pH, leading to loss of the 
lysosomal function as well as the fusion ability with autophagosomes [Deng et al., 2009]. On the 
contrary, high levels of cholesterol can increase mitochondrial membrane condensation. This can 
occur due to deficiency in caveolins, proteins that reside in lipid rafts microdomains and that bind 
cholesterol, promoting an increase of influx and accumulation of free cholesterol. Consequently, 
it occurs a decreased efficiency of the respiratory chain and intrinsic antioxidant defenses leading 
to accumulation of reactive oxygen species (ROS) and eventually cell death [Bosch et al., 2011]. 
The bioactive triterpenoids have structural similarities to cholesterol (Figure 7) and are 
good candidates to interact with biomembranes, potentially modulating their structural properties 
and leading to functional changes of proteins associated to membranes. A previous report 
described the ability of both UA and OA to perturb membrane domains rich in cholesterol and, 
therefore, affecting the lipid membrane physical properties [Prades et al., 2011]. Also recently, it 
was shown the potential of OA to strongly decrease the phosphorylation of AKT and lipid rafts-
mediated mTORC1 and mTORC2 signaling, as well as their contents decreased in the lipid raft 
fractions. Moreover, addition of exogenous cholesterol restored the signaling events disrupted by 
OA in breast cancer cells [Chu et al., 2010]. All these aspects confer a certain capacity of 
pentacyclic triterpenoids to interfere with cholesterol homeostasis and associated cellular 
functions, which may be explored as a novel approach to disrupt the survival of resistance of 
tumor cells. 
The triterpenoids UA and OA have also been considered as potential good drugs for the 
treatment of hyperlipidemia, which also indicate their potential to control cholesterol levels in 
vivo. Azevedo et al. reported the ability of UA to ameliorate the lipid profile in rats [Azevedo et al., 
2010]. It has also been reported that both triterpenoids are able to inhibit acylCoA:cholesterol 
acyltransferase (a enzyme that is require for the storage of cholesterol), promoting decreased 
levels of cholesterol in vivo [Lin et al., 2009]. Effects on cholesterol biosynthesis has also been 
associated with UA, where it was reported its capacity to increase the mRNA expression of 
cholesterol 7α-hydroxylase and to accelerate the conversion of cholesterol into bile acid, which 
may explain the reduction in cholesterol and low density lipoprotein-cholesterol levels in the 
circulation induced by UA [Xue et al., 2006]. Recently, a study by Jia et al. indicates that UA 
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regulates hepatic lipid metabolism by acting as a peroxisome proliferator-activated receptor 
(PPAR-α) agonist in vitro. UA altered the expression of key genes in lipid metabolism, significantly 
reducing intracellular triglyceride and cholesterol concentrations in hepatocytes, but without 
being a direct ligand of PPAR-α [Jia et al., 2011]. 
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Objectives of the work 
 
 
These works are integrated in the Nutriomics and Pharmacology Group of the 
Department of Biology, University of Minho, that studies the cellular and molecular mechanisms 
of action of health improving properties of phytochemicals. In this regard, many natural 
compounds and plant extracts have been characterized as potential anticancer drugs or 
sensitizers of chemotherapeutics. A previous work in our group reported the potential of UA to 
induce cell death and to inhibit proliferation in colorectal cancer cells. This natural triterpenoid 
UA was also shown to enhance the efficacy of the chemoterapeutic 5-fuorouracil, to activate JNK 
signaling and to modulate molecular markers of autophagy. 
In the present report, we decided to evaluate the applicability of two isomer triterpenoids, 
UA and OA, to induce cell death and modulate autophagy in the HepG2 human hepatocellular 
carcinoma cell line. Resistance to chemoterapeutics and survival of cancer cells in poor 
vascularised central areas of tumors are mediated by autophagy. Therefore, starvation-induced 
autophagy was used in this work to mimic metabolic stress in cancer cells and to study the 
potential anticancer effects of UA and OA in HepG2 cells. The mechanisms of cell death induced 
by the triterpenoids was investigated using pharmacological inhibitors of several molecular 
targets and signalling pathways, and cell viability measured by MTT assay and PI staining. 
Considering previous effects of UA in autophagy molecular markers, we also studied whether cell 
death induced by these triterpenoids is mediated by autophagic flux inhibition. Triterpenoids are 
structurally similar to cholesterol, which is an important component of cell membranes and 
involved in central cellular functions. Therefore, the potential of these compounds to disrupt 
cholesterol homeostasis was also explored in this work. With this study we intend to give one 
more step ahead in the elucidation of the mechanisms of action of triterpenoids as potential 
anticancer compounds.  
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1. Chemicals and antibodies 
 
Oleanolic acid (OA), ursolic acid (UA), 3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide (MTT), methyl-β-cyclodextrin (MβCD), Minimum Essential Medium Eagle (MEM), MEM 
without L-glutamine, RPMI-1640, antibiotic/antimycotic solution, bovine serum albumin (BSA), 
  N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), Monodansyl-cadaverine (MDC) 
and chloroquine (CQ) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Rapamycin (Rap) 
was purchase from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Protease inhibitors PepA 
and E64D were from PeptaNova GmbH (Germany). 2’,7’-Dichlorodihydrofluorescein diacetate 
(DCF) was purchased from Molecular Probes (Eugene, OR, USA). Fetal bovine serum was bought 
from Lonza (Verviers, Belgium). The source of primary antibodies were the following: anti-
phospho-mTOR from Cell Signaling (Danvers, MA, USA); ant-rabbit p62 (SQTM1) from Enzo Life 
Sciences (Lorrach, Germany); anti-MAPLC3 (clone 5F10) from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA, USA); and anti-β-actin from Sigma-Aldrich. Secondary antibodies HRP donkey 
anti-rabbit and sheep anti-mouse were purchased from Santa Cruz Biotechnology. 
 
 
2. Cell culture 
 
HepG2 cells (human hepatocellular liver carcinoma cell line), obtained from the 
American Type Culture Collection (ATCC), were maintained in culture in 75 cm
2 polystyrene 
flasks (TPP, Switzerland) with MEM medium, containing 10% FBS, 1% antibiotic–antimycotic 
solution, 1 mM sodium pyruvate, 10 mM HEPES and 2.2 g/l sodium bicarbonate under an 
atmosphere of 5% CO2 and 95% air at 37°C. HCT116 cells (human colorectal carcinoma cell 
line) were kindly provided by Prof. Raquel Seruca from IPATIMUP, Porto. The cell line was 
maintained in culture in 25 cm
2 polystyrene flasks (TPP, Switzerland) with RPMI 1640 medium, 
containing 6% FBS, 1% antibiotic–antimycotic solution, 0,1 mM sodium pyruvate, 10 mM HEPES 
and 2 g/l sodium bicarbonate under an atmosphere of 5% CO2 and 95% air at 37°C. 
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3. MTT reduction assay 
 
A MTT reduction assay was performed to study the potential of test compounds to 
decrease the number viable cells, as previously described [Lima et al., 2011]. Briefly, HepG2 
cells were plated in 24-multiwell culture plates at 0.1x106 cells per well one or two days before 
incubation with test compounds (for pre-incubation and co-incubation procedures, respectively). 
In the pre-incubation procedure, HepG2 were incubated with test compounds for 24h followed by 
a period of 48h with fresh complete medium or fresh starvation medium (MEM medium without 
glutamine and FBS). In the co-incubation procedure, HepG2 were incubated with test compounds 
dissolved in complete medium or starvation medium for 48h. One hour before the end of the 
incubation period MTT (final concentration 0.5 mg/ml) was added to each well. Then, the 
medium was removed, and the formazan crystals formed by the cell’s capacity to reduce MTT 
were dissolved with a 50:50 (v/v) DMSO:ethanol solution, and absorbance measured at 570 nm 
(with background subtraction at 690 nm). The results were expressed as percentage relative to 
the control (cells without any test compound, vehicle only – DMSO 0.5%). The concentration of 
test compound that decreases the number of viable cells to 50% (IC50) was calculated using 
mathematical modeling with the program GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, 
CA, USA). 
 
 
4. Cell death analysis by PI staining 
 
HepG2 cells were plated in 24-multiwell culture plates at 0.1x106 cells per well. After 
treatment with different incubation times and/or different concentrations of OA, cells were 
collected (both floating and attached cells) and washed in ice cold PBS containing 6% (v/v) FBS. 
Cells were then resuspended in ice cold PBS with propidium iodide (PI) and Hoechst, added to a 
final concentration of 25 µg/ml and 5 µg/ml, respectively. Twenty microliters of the stained cell 
suspension were placed on microscope slides and overlaid carefully with a coverslip. 
Immediately, cells were visualized on a fluorescent microscope and photos taken from different 
fields. The percentage of dead cells (PI positive) was calculated from the ratio between PI positive 
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cells and total number of cells (visualized with Hoechst staining), from a count higher than 500 
cells per slide. 
 
 
5. Western blotting 
 
HepG2 cells were plated in 6-multiwell culture plates at 0.5x106 cells per well. After 
treatment with different incubation times or different concentrations of compounds, cells were 
washed with PBS and lysed for 15 min at 4ºC with ice cold RIPA buffer (1% NP-40 in 150 mM 
NaCl, 50 mM Tris-HCl (pH 8), 2 mM EDTA) containing 1 mM PMSF, phosphatase inhibitors (20 
mM NaF, 20 mM Na2V3O4) and protease inhibitor cocktail (Roche, Mannheim, Germany). Protein 
concentration was quantified using the Bio-Rad DC protein assay (Bio-Rad Laboratories, 
Hercules, CA, USA) and BSA used as protein standard. For Western blot, 20 μg of protein was 
resolved in SDS-polyacrylamide gel and then electroblotted to a polyvinylidene difluoride 
membrane (Millipore, Billerica, MA, USA). Membranes were blocked in TPBS (PBS with 0.05% 
Tween-20) containing 5% (w/v) nonfat dry milk, washed in TPBS and incubated with primary 
antibody overnight. Then, after washing, membranes were incubated with secondary antibody 
conjugated with horseradish peroxidase and immunoreactive bands were detected using the 
Immobilon solutions (Millipore) under a chemiluminescence detection system, the ChemiDoc 
XRS (Bio-Rad Laboratories). Band area intensity was quantified using the Quantity One software 
from Bio-Rad. β-Actin was used as loading control. 
 
 
6. Immunofluorescence analysis 
 
HepG2 cells were plated in chamber slides at 0.1x106 cells per well. After treatment cells 
were fixed for 30 min with 4% PFA in PBS, washed twice with PBS, followed by permeabilization 
with 0.2% Triton-X-100 for 2 min and by blocking with 5% normal goat serum diluted in PBS 
containing 1% BSA and 0.3% Triton-X-100 for 20 min. Chamber slides were incubated with 
primary antibodies overnight at 4ºC in humidity chambers with anti-mouse LAMP-2 (1:200) from 
the Developmental Studies Hybridoma Bank (University of Iowa, IA, USA) and anti-mouse LC3 
(1:50) from Santa cruz. The monoclonal antibody LAMP-2 (clone H4B4) developed by August JT 
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and Hildreth JEK was obtained from the Developmental Studies Hybridoma Bank developed 
under the auspices of the NICHD and maintained by The University of Iowa, Department of 
Biology, Iowa City, IA 52242. After incubation with primary antibodies, slides were washed in 
PBS containing 0.25% BSA and 0.1% Triton X-100, and incubated with secondary antibodies 
(goat anti-mouse IgG Alexa Fluor 488 or goat anti-rabbit Alexa Fluor 488, Invitrogen) for 1h at 
room temperature. Slides were washed with TPBS and mounted with Vectashield antifading 
solution (Vector Laboratories, Inc., Peterborough, UK). Immunofluorescence signal were 
visualized under a fluorescent microscope (Olympus IX71) and photos taken from different fields. 
 
 
7. Measurement of reactive oxygen species 
 
To determinate the levels of reactive oxygen species (ROS) by flow cytometry, cells were 
seeded in petri dishes (60 mm) with 1x106 cells and treated with OA overnight. After that, cells 
were washed with PBS and incubated with 2’,7’-Dichlorodihydrofluorescein diacetate (DCF) at a 
final concentration of 10 μM for 30 min, 37ºC. After incubation, cells were washed with PBS, 
collected and washed with ice cold PBS, centrifuged at 500 xg for 5 min and resuspended in 
PBS. Samples were then run on a flow cytometer (Beckman-FC500, Beckman Coulter) and ROS 
levels expressed as the ratio between mean fluorescence intensity of each sample and 
autofluorescence. 
 
 
8. Statistical analysis 
 
Data are expressed as the mean ± SEM of at least 3 independent experiments. Statistical 
significances among data groups were analyzed by one-way ANOVA followed by the Newman–
Keuls multiple comparison test, or analyzed by the Student’s t-test, as appropriate, using 
GraphPad Prism 5.0 software (San Diego, CA, USA). Differences between groups were 
considered statistically significant when P≤0.05. 
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1. Effects of UA and OA in molecular markers of autophagy 
 
 
In a previous work, in our laboratory, UA was tested in colorectal cancer cells and shown 
to have anti-proliferative effects and to induce cell death by apoptosis [Xavier et al., 2009]. In the 
apoptosis-resistant HCT15 cell line, however, apoptosis did not account for all cell death induced 
by UA [Xavier et al., 2012, submitted]. In these cells, UA activated JNK and modulated molecular 
markers of autophagy, which suggested that these pathways might be involved in cell death 
[Xavier et al., 2012, submitted]. Both in HCT15 and in MCF7 breast cancer cell line, UA induced 
the levels of LC3 and p62 that, in addition with other molecular assays, suggested that UA is 
inhibiting autophagy at later steps, in particular in the fusion of autophagosomes with lysosomes 
[Xavier, 2010]. In the present study, we tested the ability of the two isomeric triterpenoids UA 
and OA to induce cell death and to modulate autophagy in the HCC HepG2 cell line. First, we 
evaluated by western blot the effects of these triterpenoids in the levels of p62 and LC3 that are 
considered good molecular markers of autophagy [Bjorkoy et al., 2009; Kouri et al., 2002]. As 
shown in Figure 8A, both UA and OA induced the accumulation of p62 and LC3-II along the time. 
Therefore, like the previous results in colon cancer cells, UA also induced the increase of 
autophagy markers in HepG2 cells. OA also present similar results, which is not surprising having 
in count the very similar structure with UA. 
 
 
 
 
 
 
 
 
Figure 8. Modulation of autophagic markers by triterpenoids and starvation in HepG2 cells. A) Effect of 25 µM of UA and OA in 
the levels of LC3 and p62 in complete medium along the time. B) Effect of starvation medium (complete medium without FBS 
and glutamine) in the levels of p-mTOR and LC3 along the time, in the presence or absence of the protease inhibitors PepA 
(pepstatin A) and E64d. 
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To compare with the effects of both UA and OA, we also induced autophagy by 
starvation, in particular with serum and glutamine deprivation as reported before [Yu et al., 
2010]. As shown in Figure 8B, starvation decreased p-mTOR levels but did not increase 
considerably the levels of LC3-II after 6h and 24h of incubation. This is in agreement with the 
recent literature, because when the autophagic flux is induced there is only a transient increase 
in LC3-II levels that then return to normal levels due to its degradation in the autolysosome 
[Kabeya et al., 2000; Mizushima et al., 2010]. Therefore, in these conditions increased 
autophagic flux can be studied using inhibitors of autophagy in later steps, such as by using the 
lysosome protease inhibitors PepA and E64d [Mizushima et al., 2010; Tanida and Waguri, 
2010]. Blocking the autophagic flux we observed, in fact, that starvation medium induced a 
higher accumulation of LC3-II as compared with complete medium, indicating therefore induction 
of autophagy. Thus, in opposition to the starvation-induced autophagic flux, increased levels of 
both LC3 and p62 by UA and OA may indicate an inhibition of autophagy at later steps (Figure 
8).  
 
 
2. Effect of UA and OA in HepG2 cell viability 
 
 
Considering that both UA and OA also remarkably increased autophagy markers in 
HepG2 cells, we then evaluated their effects on the viability of HepG2 cells by MTT assay in both 
complete and starvation medium. As shown in Figure 9A, OA induced a higher decrease of the 
number of viable cells as compared with UA at 20 µM, in both complete and starvation medium. 
On the contrary, in previous results in colon and breast cancer cells UA was much more effective 
than OA in decreasing cell viability [Xavier, 2010]. Interestingly, OA remarkably decreased the 
number of viable cells in starvation medium as compared with UA, suggesting therefore different 
modes of action of these isomer triterpenoids. Under the microscope, UA induced remarkable 
cell morphological changes with the appearance of floating cellular debris but without floating 
cells in the medium (Figure 9B). These debris increased in starvation medium and cells present 
bigger and higher number of shining vacuolar structures, but without cell death (floating cells). 
On the contrary, although OA also induced some cellular debris in complete medium, when cells  
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Figure 9. Effect of ursolic acid (UA), oleanolic acid (OA) and rapamycin (Rap) in the viability of HepG2 cells. A) Cells were 
incubated with test compounds (controls received vehicle only – DMSO) for 48h either in complete medium or starvation 
medium, and cell viability assessed by MTT reduction assay. Values are mean ± SEM of at least three independent experiments. 
*P≤0.05, ** P≤0.01, *** P≤0.001, when compared with respective control, analyzed by the Student’s t-test. +++ P≤0.001, when 
compared with same condition between different media, analyzed by the Student’s t-test. B) Representative images of the effect 
of test compounds in complete and starvation medium for 48h (bar=100μm).  
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were incubated in starvation medium for 48h, most of cells were floating with morphological 
features of cell death, confirming therefore the MTT results (Figure 9). The effect of Rap in cell 
viability was also studied to test the effects of a compound known to induce autophagy and to 
have anticancer effects [Faivre et al., 2006; Oshiro et al., 2004]. As shown in Figure 9A, HepG2 
cells were not susceptible to cell death induced by Rap, and only in starvation medium there was 
a significant but slight decrease in the number of viable cells. Also comparing the control 
situation in both media, we observe a decrease in the number of viable cells in starvation 
medium (Figure 9). This decrease is probably due to inhibition of cell proliferation during the 48h 
of incubation due to serum and glutamine starvation, since no cell death was observed under the 
microscope as shown by the absence of floating cells and cells with blebs. 
 It is not surprising that starvation-induced autophagy increases the susceptibility to cell 
death induced by other drugs, such as what happened here with OA. It is known that starvation-
induced autophagy mediates protection from apoptosis [Boya et al., 2005], and that inhibitors of 
autophagy inhibits the survival of cells under starvation [Farkas et al., 2011]. Here, although both 
UA and OA increase the levels of LC3 and p62 probably due to autophagy inhibition, only OA 
sensitized HepG2 cells to death under starvation (Figure 9). To test if OA also sensitize other cells 
to cell death under starvation, we did a similar experiment in the colorectal carcinoma cell line 
HCT116. Confirming previous results by Xavier (2010), UA was more toxic than OA in the 
HCT116 cells line (see Supplementary Fig. 1A). When the compounds were tested in starvation 
medium the number of viable cells decrease (see Supplementary Fig. 1B). However, the 
decrease was much more significant in cells treated with OA (see Supplementary Fig. 1). For UA 
the IC50 decrease from 8 µM in complete medium to 4 µM in starvation medium, after 48h of 
incubation, whereas for OA, the IC50 decrease from >>50 µM (viability was 93% at 50 µM – 
higher concentration tested) to 12 µM. These results show that OA also remarkably sensitize cells 
to death in other cell lines under starvation as compared with UA. 
To further test that UA and OA have different effects as compared with Rap, we next 
evaluated the effects of pre-incubation with test compounds in complete medium followed by a 
period of starvation of 48h without test compounds in cell viability by the MTT assay. Induction of 
autophagy by Rap 24h prior to starvation remarkably decreased cell viability induced by 48h of 
starvation (Figure 10A). This effect was in part due to cell death since floating cells were 
observed (data not shown), contrarily to the effect of Rap incubated in starvation medium (co-
incubation procedure – Figure 10A). Here, the observed decrease in cell viability was probably  
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Figure 10. Effect of Rap (A) and UA (B) in the viability of HepG2 cells, as assessed by MTT reduction assay. In the pre-
incubation regime, cells were incubated with Rap (A) or UA (B) at indicated concentrations for 24h in complete medium followed 
by a period of 48h with the indicated fresh medium without Rap or UA. In the co-incubation regime, cells were incubated with Rap 
(A) or UA (B) at indicated concentrations for 48h either in complete medium or starvation medium. Values are mean ± SEM of at 
least three independent experiments. *P≤0.05, ***P≤0.001, when compared with respective control, analyzed by the Student’s t-
test. 
++
 P≤0.01, when compared with same condition in complete medium, analyzed by the Student’s t-test. 
 
due to the presence of a less number of viable cells due to inhibition of proliferation or due to a 
decrease in cell metabolic activity induced by Rap together with starvation as compared with 
starvation alone. Therefore, autophagy induction by Rap was detrimental to cells in a following 
period of starvation-induced autophagy. This might happen because cells possess less cellular 
contents for degradation by autophagy for generation of energy and building blocks in a period of 
starvation that immediately follows other. In the case of UA, this pre-incubation procedure did not 
result in a decrease of the number of viable cells (Figure 10B). Regarding the effects of OA, 
likewise Rap, the pre-incubation procedure resulted in a decrease of cell viability (Figure 11A&B). 
However, contrarily to Rap, the effect of OA in cell viability was stronger when incubated along 
with starvation than that in the pre-incubation regime (Figure 11B). Therefore, these results 
corroborate that the effect of OA in autophagy and cell death is different than that of Rap and UA. 
Considering all the results we decided then to focus the following work in the effect of OA 
in the induction of cell death under starvation conditions. Thus, we next tested the effect of 
different concentrations of OA in cell viability by the MTT test. As shown in Figure 11B, OA 
induced a concentration-dependent decrease in the number of viable cells after 48h under 
starvation conditions, from 1 µM to 20 µM. Under starvation OA present an IC50 of 3.5 µM  
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Figure 11. Effect of oleanolic acid (OA) on the viability of 
HepG2 cells in complete (A) and starvation (B & C) medium, 
as assessed by MTT reduction assay. (A & B) In the pre-
incubation regime, cells were incubated with OA at indicated 
concentrations for 24h in complete medium followed by 
period of 48h with the indicated fresh medium without OA. In 
the co-incubation regime, cells were incubated with OA at 
indicated concentrations for 48h either in complete medium 
(A) or starvation medium (B). Values are mean ± SEM of at 
least three independent experiments. * P≤0.05, ** P≤0.01, *** P≤0.001 when compared with respective control, analyzed by 
one-way ANOVA (Newman-Keuls Multiple Comparison Test). (C) Graphic of the mathematical modelling of data present in Figure 
11B in the co-incubation regime following a bell-shaped dose-response curve, using the GraphPad Prism software. Shown in the 
graphic are the IC50 of 3.5 µM as well as the EC501 of 2.3 µM and EC502 of 9.8 µM for cell viability. 
 
(Figure 11C) whereas in complete medium is about 50 µM (Figure 11A), representing about a 
15x increase of susceptibility. 
Usually, the effect of a drug on cell viability follows a sigmoidal curve. However, in this 
case we find that the effect of OA followed a bell-shaped dose-response curve (composed of two 
sigmoidal curves) showing two EC50 values (Figure 11C). Based on the morphological 
observations after OA treatment under starvation and on the PI staining results (Figure 12), we 
believed that this effect is due to different effects of the drug in two concentration ranges. In 
particular, in the first sigmoidal curve that presents an EC50 (half maximal effective 
concentration) of 2.3 µM OA might induces a decrease of the number of viable cells due to the 
inhibition of cell proliferation (under starvation this factor will not contribute much) and/or due to 
a decrease in cells’ metabolic activity. On the other hand, in the second sigmoidal curve that 
A B 
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presents an EC50 of 9.8 µM, the effect of OA in the decrease of the number of viable cells is most 
likely due to induction of cell death in a concentration-dependent manner. This latter assumption 
is corroborated by the results of PI staining shown below. 
As shown in Figure 12A by the PI staining assay, OA induced cell death in a 
concentration-dependent manner from 5 µM to 15 µM after 48h of incubation in starvation 
medium. Cell death significantly increased from 10% in control condition to 60% and 95% with 10 
µM and 15 µM of OA, respectively. Studying cell death along the time we found that OA 10 µM 
increased significantly the number of PI positive cells only after 24 h of incubation (Figure 12B). 
These results indicate that cell death induced by OA is not abrupt and may be programmed. 
Considering the effect of OA on cell death, we then tested the ability of OA to induce 
apoptosis. Incubation of HepG2 cells with OA 15 µM in starvation medium for 48h did not result 
in nuclear condensation and cleavage of caspases and PARP1 (data not show). These results are 
not consistent with previous reports where it was shown that OA and UA induced apoptosis in 
hepatocellular carcinoma cells [Shyu et al., 2010; Yan et al., 2010]. However, those results were 
done in complete medium and with higher concentrations of drug and/or fewer cells. 
It is considered that starvation-induced autophagy protects cells from cell death by 
apoptosis, process that is used by cancer cells for survival [Boya et al., 2005; Roy and Debnath, 
2010]. This process can be reverted by small inhibitors of autophagy [Farkas et al., 2011]. Thus, 
suppression of autophagy with pharmacological agents under conditions of starvation or 
chemotherapy may significantly increase cell apoptosis and retard proliferation of  
 
 
Figure 12. Effect of oleanolic acid (OA) on cell death in HepG2 cells under starvation, as assessed by the PI staining assay. (A) 
Effect of different concentrations of OA for 48h. (B) Effect of OA 10 µM along time. Values are mean ± SEM of at least three 
independent experiments. *P≤0.05, *** P≤0.001 when compared with control by the one-way ANOVA (Newman-Keuls Multiple 
Comparison Test), 
#
 P≤0.05 when compared with each other by the Student’s t-test. NS, not significant (P>0.05) when compared 
with each other by the Student’s t-test. 
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cancer cells [Chang et al., 2011]. However, in our study, although OA seem to be modulating 
autophagy by inhibiting it, the induction of cell death by OA under starvation conditions seems to 
not involve apoptosis.  
 
 
3. OA and UA induce accumulation of acidic vacuoles 
 
 
Considering the effects of UA and OA in the modulation of autophagy molecular markers 
and the differential effects that they present on induction of cell death, we decide to further study 
their kinetics in the formation of acidic degradative compartments. Monodansylcadaverine (MDC) 
has been reported as a specific marker for autophagic-related vacuoles [Biederbick et al., 1995]. 
In addition, the accumulation of MDC-labelled vesicles correlates with the induction of autophagy 
by starvation conditions for 2h [Munafo and Colombo, 2001]. However, it is currently accepted 
that MDC does not stain nascent autophagosomes until prior to their acquisition of acidic 
properties, and, therefore, it only stains acidic compartments that include late endosomes, 
lysosomes and autolysosomes [Bampton et al., 2005]. As shown Figure 13, cells treated with UA 
for 16h showed a remarkable increase of MDC-labelled large acidic vesicles both in complete and 
starvation medium. In the case of OA, there was the appearance of few and small acidic vacuoles 
in complete medium, which remarkably increased upon treatment of cells under starvation 
conditions (Figure 13). In the case of Rap-induced autophagy conditions, accumulation of acidic 
vacuoles was only observable after inhibition of autophagy at later steps with chloroquine (Figure 
13A and Supplementary Fig. 2). However, the increase of acidic valuoles by Rap was not 
significant as compared with control condition (Figure 13A). Therefore, also here both 
triterpenoids behaved differentially than rapamycin showing an effect similar of an autophagy 
inhibitor at later steps. In addition, comparing the results between the two isomer triterpenoids 
also agrees that they act in a different way in HepG2 cells, since UA induced accumulation of 
acidic vacuoles in both normal and starvation conditions whereas OA only did that remarkably 
under starvation conditions. Importantly, this accumulation of acidic vesicles induced by OA 
under starvation might not be involved in cell death, since UA have more capacity to induce that 
in HepG2 but without significant cell death. 
The kinetics of accumulation of acidic vacuoles induced by OA were also followed in  
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Figure 13. Effect of oleanolic acid (OA) and ursolic acid (UA) in the appearance of cellular acidic vacuoles, as assessed by MDC-
staining. HepG2 cells were treated with the indicated compounds for 16h in complete or starvation medium before being stained 
with 50 µM monodansylcadaverine (MDC) for 10 minutes. Chloroquine (CQ) at 10 µM was used to observe the effects of 
rapamycin (Rap) in complete medium. (A) Quantification of the number of MDC-labelled acidic vacuoles per cell by morfometric 
analysis performed in photos taken in different areas of the samples. Values are mean ± SEM of at least three independent 
experiments. * P≤0.05, ** P≤0.01 and *** P≤0.001 when compared with control by the Student’s t-test. ++ P≤0.01 when 
compared with same treatment but in different medium by the Student’s t-test. 
### P≤0.001 when compared with each other by 
the Student’s t-test. NS, not significant (P>0.05) when compared with each other by the Student’s t-test. (B) Representative 
images of the effect of tested compounds for 16h in the appearance of cellular acidic vacuoles in HepG2 cells cultured in 
complete and starvation medium (bar=50μm).  
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HepG2 cells under starvation conditions. As shown in Figure 14, OA induced a concentration- 
and time-dependent accumulation of MDC-labelled vesicles. The effect is significant after the 
concentration of 10 µM (Figure 14A) and begins to occur after 4h of incubation, increasing the 
number of acidic vacuoles along the time (Figure 14B). These results, in addition to the levels of 
autophagy markers shown in Figure 8, indicate that OA (as well as UA) modulates autophagic flux 
very early after compound incubation.  
To complement these results we also studied the expression of LC3 and LAMP-2-
associated lysosomal marker by immunofluorescence. Under autophagy induction and inhibition 
at later steps LC3 positive punctae accumulate in cells due to the increase of autophagosomes. A 
portion of these LC3 punctae may or may not be colocalized with LAMP-2 staining, depending on 
the interference that we may be inducing to the autophagic flux [Bampton et al., 2005]. 
Unfortunately, we were not able to get a positive immunostaining of LC3 with the antibody and 
conditions that we used. However, as shown before, we observed a remarkably increase of LC3 
levels by western blot (Figure 8). Regarding the LAMP-2 we get a positive signal and we observe 
that stained vesicles seem to increase in cells treated with UA or OA as compared to the control 
condition under starvation (see Supplementary Fig. 3). But interestingly, vesicles stained by 
 
 
 
 
Figure 14. Effect of oleanolic acid (OA) in the accumulation of acidic vacuoles in HepG2 cells under starvation medium, as 
assessed by MDC-staining. Cells were incubated with different concentrations of OA for 16h (A) or along the time with 10 µM OA 
(B) before being stained with 50 µM of monodansylcadaverine (MDC) for 10 minutes. Represented are the quantification of the 
number of MDC-labelled acidic vacuoles per cell by morfometric analysis performed in photos taken in different areas of the 
samples. Values are mean ± SEM of at least three independent experiments. ** P≤0.01 and *** P≤0.001 when compared with 
control (A) or with 1h-control (B) by the one-way ANOVA (Newman-Keuls Multiple Comparison Test). 
# P≤0.05 and ## P≤0.01 
when compared with each other by the Student’s t-test. NS, not significant (P>0.05) when compared with each other by the 
Student’s t-test. 
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LAMP-2 antibody were larger in cells treated with OA being possible to observe the contour of the 
structures in the amplification used, whereas in cells treated with UA we only observed bright 
LAMP-2-labbeled punctae (see Supplementary Fig. 3). Although these results need to be 
confirmed in following experiments, these larger lysosomes induced by OA but not by UA may 
reflect or be involved in the cell death induced specifically by OA in starvation conditions.  
 
 
4. Autophagy inhibitors do not protect cells from death induced by OA 
 
 
In the present work we have shown that OA induces significant cell death independent of 
apoptosis in HepG2 cells under starvation conditions. Concomitant with this, we also found 
accumulation of several markers of autophagy, such as LC3, p62 and acidic vesicles. Therefore, 
we speculate whether autophagy would be involved in OA-induced cell death under starvation 
conditions. If autophagy is induced above a critical threshold it can induce cell death due to 
extensive degradation of cytoplasmatic material [Galluzzi et al., 2009]. As a control of this 
condition, we used the pre-incubation regime with Rap described above that leads to cell death in 
a subsequent period of starvation-induced autophagy. As shown in Figure 15A, Rap pre-treatment 
increased the susceptibility of cells to die under a subsequent starvation period, which was 
prevented by CQ but not by the PepA + E64d. Both of these autophagy inhibitors, that act at later 
steps, were used in non-toxic concentrations (Figure 15A) and in effective concentrations as can 
be observed in Figure 8B and Figure 13A for PepA + E64d and CQ, respectively. The fact that 
PepA + E64d did not work as CQ protecting cell death induced by Rap could be because they are 
degraded faster than CQ and, therefore, they are inappropriate to be used for 48h in the 
concentrations tested. On the other hand, the cell death induced by OA under starvation 
conditions was not prevented by CQ and PepA + E64d (Figure 15B). On the contrary, co- 
incubation of these inhibitors with OA even promoted slightly the decrease of cell viability. 
Therefore, this result does not support the idea that OA is inducing cell death by increasing 
chronically autophagy, which is in agreement with our previous results. 
In turn, as discussed above, the accumulation of LC3, p62 and acidic vesicles by OA is 
most likely due to inhibition of autophagy at later steps. To check if inhibition of autophagy was 
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Figure 15. Effect of autophagy inhibitors in the cell death induced by rapamycin (Rap) and oleanolic acid (OA) in HepG2 cells, as 
assessed by MTT assay. A) Cells were pre-incubated with 50 nM Rap (controls received vehicle only – DMSO) for 24h in complete 
medium followed by period of 48h with fresh starvation medium containing 10 µM CQ or PepA/E64d (10µg/ml, each). B) Cells 
were incubated with 10 µM OA for 48h in starvation medium in the presence of 10 µM CQ or PepA/E64d (10µg/ml, each). 
Values are mean ± SEM of at least three independent experiments. ** P≤0.01, *** P≤0.001, when compared with respective 
control, analyzed by the Student’s t-test. 
+P≤0.05 when compared with the respective test compound alone, analyzed by the 
Student’s t-test. 
## P≤0.01, ### P≤0.001, when compared with each other by the Student’s t-test. NS, not significant (P>0.05) 
when compared with each other by the Student’s t-test. 
 
 
involved in OA-induced cell death we decreased autophagic flux by using pharmacological 
inhibitors of autophagosome formation. For that we used the inhibitors 3-MA, LY-294002 and 
wortmannin; but when incubated alone, all of them already decreased cell viability of HepG2 cells 
under starvation as measured by the MTT assay (data not show). That is not surprising since it is 
known that these inhibitors lack of specificity to class III PI3K, inhibiting also class I PI3K, which 
affect cell growth and survival [Farkas et al, 2011]. A possible solution would be to inhibit 
autophagosome formation by genetic tools, such as with the use of small interfering RNA 
targeting Atg5 or Beclin 1. However, under starvation conditions, inhibition of autophagy by any 
mean result in cell death [Boya et al., 2005; Farkas et al., 2011], being therefore difficult to 
speculate whether OA is inducing cell death due to inhibition of autophagy at later steps. 
Nevertheless, here we have used two isomer triterpenoids, and because UA is more effective 
inhibiting autophagy than OA, but only OA is inducing cell death under starvation conditions, it 
indicates that the toxic effect of OA is probably independent of inhibition of autophagy at later 
steps. Altogether, these data point out that OA is modulating autophagy and doing something 
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 else to the cells that promotes cell death under starvation conditions. 
To explore other possible mechanisms of induction of cell death by OA in HepG2 cells 
under starvation conditions, we have further tested other inhibitors of molecular targets and/or 
signalling pathways using the MTT assay. In a previous work, it was shown that UA induced 
apoptosis and modulation of autophagy proteins through JNK pathway in the colorectal 
carcinoma HCT15 cells [Xavier et al., 2012, submitted]. The stress-activated protein kinase JNK 
has been implicated in many cellular events including apoptosis signalling and more recently 
autophagic cell death [Cheng et al., 2008; Wong et al., 2010]. In line with this, we also tested the 
use of the JNK inhibitor SP600125 (SP) in co-incubation with OA. The results showed that SP 
does not prevent cell death induced by OA (data not shown), suggesting that it is not dependent 
on activation of JNK.  
Mitochondrial membrane permeabilization may result from bioenergetic failure, which 
may occur due to nutrient depletion combined with the impossibility of recruiting endogenous 
nutrients by autophagy-dependent catabolic reactions [Boya et al., 2005; Plas and Thompson, 
2002]. On the other hand, autophagy is the process that leads to the removal of damaged 
mitochondria and its inhibition has been shown to increase the production of ROS [Tal et al., 
2009; Zhang et al., 2007]. Also in the study of Xavier et al. (2012, submitted), the antioxidant N-
acetylcysteine (NAC) was found to reduce partially the apoptosis-like cell death induced by UA in 
HCT15 cells, suggesting an implication of ROS. Therefore, we also test here the possible 
involvement of ROS in the OA-induced cell death under starvation conditions by using known 
antioxidants such as NAC, α-tocoferol and glutathione ethyl ester (GSH-EE – a cell permeable 
form of glutathione). However, none of these antioxidants protected HepG2 cells against death 
induced by OA (data not shown). Corroborating these results we have measured the cellular 
content of ROS and instead of an increase we observed a decrease of ROS induced by OA. As 
shown in Supplementary Fig. 4, ROS levels measured by flow cytometry using the DCF probe 
decreased about 35% in the presence of OA as compared with control. This decrease in ROS 
levels may indicate a decrease of oxidative phosphorylation activity in the mitochondrial electron 
transport chain induced by OA, which can be detrimental in a condition of starvation. To test if 
there was also some effect of OA on the mitochondrial membrane potential we also measured it 
by flow cytometry with the fluorescent probe tetramethylrhodamine methyl ester (TMRM), but we 
were not able to get good stain in preliminary experiments (data not shown). Therefore, we 
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should establish better conditions of HepG2 cells’ staining with TMRM and/or JC-1 probes in 
future experiments to investigate whether OA affect mitochondria number and activity.  
 
 
5. Methyl-β-cyclodextrin protects against OA-induced cell death 
 
 
Cholesterol is an essential component of cellular membranes and controls its physical 
properties and important biological functions [Deng et al., 2009]. Considering the structural 
similarity of triterpenoids with cholesterol we hypothesized that OA could be promoting cell death 
by changing cholesterol homeostasis. To test that we have used methyl-β-cyclodextrin (MβCD) - a 
polymer able to decrease membrane cholesterol content [Ohtani et al., 1989]. As shown in 
Figure 16, when MβCD was added 3 hours after addition of the triterpenoid, the cell death 
induced by OA in HepG2 cells under starvation conditions were significantly prevented. The 
protection of cell death was in a concentration-dependent manner, except for the highest 
concentration tested in which there was some toxicity of MβCD alone. Since removal of 
membrane-associated cholesterol by MβCD prevented OA-induced cell death, it indicates that this 
triterpenoid is interfering with cholesterol levels and cellular functions that result in toxic effects 
under starvation conditions. However, due to the lipophilic nature of OA and structural similarity 
with cholesterol, we cannot exclude that MβCD is protecting cells against death by removing also 
OA. In an attempt to avoid this possibility MβCD was added to the culture medium 3 hours after 
OA to allow its internalization and induction of cellular effects. In preliminary experiments, MβCD 
was also added 6 and 24 hours after OA incubation and protection of cell death was also 
observed, but of less extent and decreasing with time (data not shown). This indicates that MβCD 
is preventing OA-induced cell death most likely by removing cholesterol from cellular membranes. 
We have also tested an inhibitor of cholesterol synthesis to check whether it has the 
same effect of OA under starvation conditions or if in combination with OA it would prevent cell 
death. For that we used pravastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A 
[Tsujita et al., 1986], at 1 µM and nor cell death was induced by it alone, nor it prevented cell 
death induced by OA (data not shown). The lack of any effect of pravastatin may indicate that the 
dose used was not effective decreasing cholesterol levels. That should be confirmed in future 
experiments by quantifying cellular cholesterol levels. 
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Figure 16. Effect of methyl-β-cyclodextrin (MβCD) on oleanolic acid (OA)-induced cell death of HepG2 cells under starvation 
conditions. Cells were incubated with OA 10 µM and, 3h after, MβCD was added at the indicated concentrations. Cell viability was 
measured 48h after OA incubation by the MTT assay. Values are mean ± SEM of at least three independent experiments. *** 
P≤0.001, when compared with respective control, analyzed by the Student’s t-test. # P≤0.05, ## P≤0.01, when compared with 
each other by the Student’s t-test. 
+ P≤0.05, +++ P≤0.001, when compared with the respective compound alone, analyzed by the 
Student’s t-test. 
 
 
Considering that the removal of cholesterol with MβCD protected OA-induced cell death, 
that indicates that OA may be increasing cholesterol content of cellular membranes to levels that 
have implications in cell viability under starvation conditions. Increased cholesterol content in 
membranes generally decreases its fluidity that, in cells, are associated with mitochondrial 
membrane condensation that leads to lower efficiency of the respiratory chain and increased 
production of ROS [Bosch et al., 2011]. Free cholesterol overload also induced cell death in 
smooth muscle cells accompanied with increased ROS levels and autophagy induction [Xu et al., 
2010]. However, here we observed lower levels of ROS in cells incubated with OA as compared 
with controls. In addition, treatment of HepG2 cells with OA seems to inhibit autophagy at later 
steps by affecting fusion of autophagosome with lysosomes. But previous results have found that 
removal of cholesterol from membranes affect autophagosome-lysosome fusion and lysossomal 
membrane permeability and pH [Koga et al., 2010; Deng et al., 2009], not corroborating, 
therefore, the notion that OA is increasing cholesterol levels. But because UA also inhibited 
autophagy without having the same effect in cell viability as OA, it denotes that we are in the 
presence of a different effect that is specific of OA. 
Interestingly, it was reported recently that OA and UA can integrate in lipid rafts (domains 
rich in cholesterol and sphingomyelin) decreasing their cholesterol content [Bayer et al., 2011; 
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Chu et al., 2010; Koga et al., 2010; Prades et al., 2011]. This interference with cholesterol 
homeostasis and structure of lipid rafts can explain triterpenoid’s distinct biological effects by 
alterations of membrane lateral heterogeneity that will affect pivotal cellular functions, such as 
membrane-associated proteins related to such domains, signal transduction pathways, fusion of 
lysosomes with autophagosomes and endocytic pathways. Removal of cholesterol from lipid rafts 
induced by triterpenoids may indirectly increase the cholesterol content in the remaining 
membranes fractions (rich in phosphoglycerides) or along the boundaries between both, which 
will affect also the function of the fluid phosphoglyceride membrane regions [Brown, 1998]. 
Therefore, an hypothesis for the protection afforded by the MβCD from OA-induced cell death 
would be that MβCD is removing the harmful high cholesterol content present in the fluid 
membrane regions that was withdraw from the lipid rafts by OA. But what would explain the 
difference between UA and OA? Although these two compounds are isomers they differ in a 
position of a methyl group and recently two different works also found differences in activity 
between both. OA, but not UA, was able to possess photoprotection against ultraviolet A radiation 
(UVAR) in human keratinocytes; both compounds integrate in the lipid rafts but only OA inhibited 
UVAR-induced ceramide formation in lipid rafts [Bayer et al., 2011]. On the other hand, Prades et 
al. (2011) used synthetic model membranes and found that UA are able to segregate cholesterol 
from lipid rafts but maintains their structural order, whereas OA can have a deeper penetration in 
membranes reducing the structural organization of lipid rafts by influencing its fluidity and 
disturbing the presence of the liquid ordered cholesterol-rich domains. Interestingly, we found 
that OA, but nor UA, induced bigger vacuolar LAMP-2-labbeled structures, which may link to 
different effects that these compounds have in cholesterol-rich domains of lysosomes. LAMP-2 
associates in a dynamic manner with these lipid microdomains at the lysosomal membrane for 
regulated degradation in these regions [Rodriguez-Navarro and Cuervo, 2010]. Therefore, bigger 
lysosomal structures with high content of LAMP-2 indicate lower cholesterol levels and disruption 
of these lipid microdomains by OA, which is in agreement with observations by Prades et al. 
(2011). 
But a question remains to be answered: why these effects of OA greatly predispose cells 
to death under starvation conditions? OA may be compromising the survival of cells under 
starvation due to inhibition of autophagy. However, UA also inhibits autophagy but did not induce 
extensive cell death. During metabolic stress autophagy inhibition also leads to apoptotic cell 
death [Boya et al., 2005], and that was not observed here also. But if HepG2 are apoptotic 
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defective cells the outcome of autophagy inhibition would be necrosis or necroptosis [Degenhardt 
et al., 2006; Farkas et al., 2011]. In our case, it may be happening a possible energy fall 
together with autophagy inhibition and lysosomal dysfunction that will lead to some kind of 
lysosomal-related cell death, which needs to be explored in further studies. 
 In conclusion, we have found that OA, but not its isomer UA, are able to induce cell 
death in HCC HepG2 cells under starvation, probably due to the disruption of cholesterol 
homeostasis and function in membranes and in cholesterol-rich lipid domains. OA can be viewed 
in the future as a specific drug for cancer treatment in particular cell physiological conditions, 
such as under metabolic stress that happens in central areas of tumors, or for sensitizing 
resistant cancer cells to death during chemotherapy. 
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1. Final remarks and conclusions 
 
 
Autophagy is induced in response to both anticancer therapy and in central areas of the 
tumor as a survival mechanism during these periods of metabolic stress. Inhibition of cellular 
self-digestion under starvation leads to cell death and is considered a novel approach for the 
treatment of cancer. In this study, we investigate the effect of two isomers triterpenoids, UA and 
OA, as potential chemotherapeutic agents of hepatocellular carcinoma cells. Our findings 
demonstrated that HepG2 cells are more susceptible to death induced by OA than by UA both in 
normal growth and starvation conditions. In addition, OA sensitized dramatically HepG2 cells to 
cell death under starvation conditions, a mechanism that seems to be maintained also in other 
cancer cells, such as in colorectal HCT116 cells. Comparing the effects of triterpenoids with that 
of Rap in cell death and expression of several autophagic markers indicate that these compounds 
have opposing effects in modulation of autophagy. Both OA and UA induce remarkable 
accumulation of acidic vacuoles and the cellular levels of LC3 and p62, suggesting, therefore, 
that these compounds act as autophagy inhibitors at the later steps of the process. However, 
only OA, but not UA, caused significant cell death under starvation conditions, which indicates 
that autophagy inhibition is probably not the cause of toxicity of OA under starvation. That was 
confirmed by the use of pharmacological inhibitors of autophagosome formation, which also did 
not prevent OA-induced cell death. Thus, autophagy seems to be not directly involved in cell 
death induced by OA, but together with other cellular processes may contribute to the fate of 
death of HepG2 cells under starvation conditions. 
In following studies, we also have shown that ROS and JNK signalling seem to not be 
involved in OA-induced cell death. Also, cell death induced by OA under starvation conditions 
seems to not be apoptotic related. Considering the structural similarity of cholesterol with 
triterpenoids and that cholesterol is an essential component of cellular membranes and control 
important biological functions, we investigated whether OA could be promoting cell death by 
changing cholesterol homeostasis. Removing cholesterol from membranes we observed that OA-
induced cell death was almost entirely reverted. In addition, OA, but not UA, was also able to 
induce bigger lysosome structures with increased LAMP-2 immunostaining. Based on these 
results and that of recently published in the literature, we suspect that OA is interfering with 
cholesterol levels in lipid rafts decreasing their structural organization and fluidity. This needs to 
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be confirmed in further studies, but that would explain the different cellular effects between OA 
and UA. The methyl group of UA at C19 in the E-ring of the pentacyclic backbone makes that 
structure more rigid as compared with OA, which could influence the location of the pentacyclic 
moiety within the lipid bilayer and its effect on the lipid raft membrane domains. 
The specific effect of OA on viability of cells under starvation conditions may, therefore, 
result from the ability of this triterpenoid to reduce the structural organization of cholesterol-rich 
domains that, in cells under metabolic stress, will have profound implications in several 
important cellular structures and activities, such as lysosomes, autophagy, cell signaling, 
endocytosis and mitochondria activity. 
 
 
2. Future perspectives 
 
 
With this study, a novel activity was found for OA that are specific for starvation 
conditions and with possible applications in cancer treatment. However, many questions remain 
to be answered, in particular the molecular mechanisms of induction of cell death by OA in 
HepG2 cells under starvation conditions. Therefore, in following studies experiments should be 
conducted in order to depict this interesting effect of OA. These cells, although originally isolated 
from an hepatocarcinoma, are metabolically competent and resemble relatively well the biological 
activities of normal hepatocytes. UA are usually more toxic than OA, but in these cells the 
contrary was found. Thus, which are the particularities of HepG2 cells that make them more 
susceptible to OA as compared with other cells? Would it be that because of their high metabolic 
activity these cells depend more on functional membrane cholesterol-rich domains, which can be 
disrupted by OA? Or due to interferences in the cellular lipid metabolism? 
Related with the molecular mechanism of induction of cell death by OA much more 
needs to be investigated. Based in our experiments, OA-induced cell death under starvation 
conditions seems to not depend on ROS, JNK activity, autophagy inhibition and are not through 
apoptosis. We should explore in future experiments the possible involvement of programmed 
necrosis (necroptosis) and/or the lysosomal-type of cell death. In addition, disruption of calcium 
homeostasis can also be involved and also dependent on pertubation of cholesterol content in 
membranes. To this regard, the assessment of cholesterol content in membranes and lipid rafts 
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fractions should be analysed in cells treated or not with OA under starvation conditions. 
Expression of proteins that localized in microdomains rich in cholesterol, such as AKT and 
SNAREs should be measured in lipid rafts fractions by western blotting. Other lipid rafts-related 
proteins, such as caveolin 1 (CAV-1), should also be assessed by immunofluorescence. In 
addition, the effect of addition of exogenous cholesterol to cells, instead of the removal as done 
here, on the OA-induced cell death should also be evaluated. The experiments done to assess the 
mitochondrial membrane potential with TMRM should be repeated, or done with other probe like 
JC-1, to understand if mitochondria are entering in an energetic failure, which may contribute to 
cell death. The expression of pAMPK by western blotting should also be evaluated to check the 
possible energy fall (low ATP values).  
The description and understanding of the cellular and molecular mechanisms of action of 
OA in these particular conditions of metabolic stress will help in the future to the possible use of 
OA as specific drug for cancer treatment in particular cell physiological conditions. 
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Supplementary Fig. 1. Effect of ursolic acid (UA) and oleanolic acid (OA) in the viability of HCT116 cells, as assessed by MTT 
reduction assay. Cells were incubated with UA or OA at indicated concentrations for 48 h in complete (A) or starvation (B) 
medium. Values are mean ± SEM of at least three independent experiments. * p≤0.05 and *** p≤0.001 when compared with 
control by the one-way ANOVA (Newman-Keuls Multiple Comparison Test). 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 2. . Effect of rapamycin (Rap) and chloroquine (CQ) in the appearance of cellular acidic vacuoles, as 
assessed by MDC-staining. HepG2 cells were treated with the indicated compounds for 16 h in complete medium before being 
stained with 50 µM monodansylcadaverine (MDC) for 10 minutes. Shown are representative images of three independent 
experiments (bar=50μm).  
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Supplementary Fig. 3. Effect of ursolic acid (UA) and oleanolic acid (OA) on LAMP-2A levels, as assessed by imunofluorescence. 
Compounds were incubated 16 h in starvation medium before imunostaining with anti-mouse LAMP-2 antibody (1:200). Images 
are representative of two independent experiments (bar=50μm). 
 
 
Supplementary Fig. 4. Effect of oleanolic acid (OA) in the levels of reactive oxygen species (ROS). HepG2 cells were incubated 
with OA 10 µM (control received vehicle only – DMSO) for 16 h in starvation medium and stained in the end with 10 μM DCF for 
30 min, at 37ºC, and ROS levels mesuared by flow cytometry. ROS levels expressed as the ratio between fluorescence intensity of 
each sample and autofluorescence are: control – 86.6; OA – 56.1. Shown are representative distributions of cells labelled with 
DCF from two independent experiments. 
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